China Jo-Jo Drugstores 10-Q 14 Nov 18 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2018	Nov. 13, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	CHINA JO-JO DRUGSTORES, INC.
Entity Central Index Key	1,413,263
Trading Symbol	CJJD
Amendment Flag	false
Current Fiscal Year End Date	--07-30
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,019
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		28,936,778

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Mar. 31, 2018
CURRENT ASSETS
Cash	$ 6,922,357	$ 15,132,640
Restricted cash	16,786,612	16,319,551
Financial assets available for sale	162,224	175,140
Notes receivable	223,954	279,082
Trade accounts receivable	7,830,713	8,322,393
Inventories	13,799,438	13,429,568
Other receivables, net	3,826,619	3,098,079
Advances to suppliers	3,234,939	3,447,452
Other current assets	1,484,108	2,116,237
Total current assets	54,270,964	62,320,142
PROPERTY AND EQUIPMENT, net	2,538,901	2,843,640
OTHER ASSETS
Long-term investment	42,268	40,890
Farmland assets	734,951	796,286
Long term deposits	2,269,241	2,501,968
Other noncurrent assets	1,279,651	1,253,352
Intangible assets, net	3,567,044	4,056,414
Total other assets	7,893,155	8,648,910
Total assets	64,703,020	73,812,692
CURRENT LIABILITIES
Accounts payable, trade	22,513,388	25,259,526
Notes payable	15,509,129	19,180,200
Other payables	4,823,881	4,272,523
Other payables - related parties	726,670	850,342
Customer deposits	4,435,964	4,040,867
Taxes payable	91,613	366,040
Accrued liabilities	1,108,740	841,993
Total current liabilities	49,209,385	54,811,491
Purchase option and warrants liability	227,635	138,796
Total liabilities	49,437,020	54,950,287
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common stock; $0.001 par value; 250,000,000 shares authorized; 28,936,778 and 28,936,778 shares issued and outstanding as of September 30, 2018 and March 31, 2018	28,937	28,937
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of September 30, 2018 and March 31, 2018
Additional paid-in capital	43,697,909	43,599,089
Statutory reserves	1,309,109	1,309,109
Accumulated deficit	(31,894,456)	(29,661,190)
Accumulated other comprehensive income	2,759,433	3,586,460
Total stockholders' equity	15,900,932	18,862,405
Noncontrolling interests	(634,932)
Total equity	15,266,000	18,862,405
Total liabilities and stockholders' equity	$ 64,703,020	$ 73,812,692

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	28,936,778	28,936,778
Common stock, shares outstanding	28,936,778	28,936,778
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
REVENUES, NET	$ 27,409,046	$ 23,491,043	$ 50,181,612	$ 45,161,411
COST OF GOODS SOLD	21,611,945	17,933,446	38,767,708	35,426,153
GROSS PROFIT	5,797,101	5,557,597	11,413,904	9,735,258
SELLING EXPENSES	5,223,523	4,350,772	9,850,501	8,267,631
GENERAL AND ADMINISTRATIVE EXPENSES	2,215,484	2,855,555	3,770,012	4,580,998
TOTAL OPERATING EXPENSES	7,439,007	7,206,327	13,620,513	12,848,629
(LOSS) FROM OPERATIONS	(1,641,906)	(1,648,730)	(2,206,609)	(3,113,371)
INTEREST INCOME	26,060	358,344	73,232	403,243
OTHER INCOME(LOSS), NET	94,582	(8,703)	(20,359)	(38,051)
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES	(81,866)	148,427	(88,840)	198,751
(LOSS) BEFORE INCOME TAXES	(1,603,130)	(1,150,662)	(2,242,576)	(2,549,428)
PROVISION FOR INCOME TAXES	(415)	18,047	56,754	38,585
NET (LOSS)	(1,602,715)	(1,168,709)	(2,299,330)	(2,588,013)
OTHER COMPREHENSIVE (LOSS) INCOME
Foreign currency translation adjustments	(1,448,661)	633,184	(827,027)	1,092,253
COMPREHENSIVE (LOSS)	$ (3,051,376)	$ (535,525)	$ (3,126,357)	$ (1,495,760)
WEIGHTED AVERAGE NUMBER OF SHARES:
Basic	28,936,778	25,214,678	28,936,778	25,214,678
Diluted	28,936,778	25,214,678	28,936,778	25,214,678
EARNINGS PER SHARES:
Basic	$ (0.06)	$ (0.05)	$ (0.08)	$ (0.1)
Diluted	$ (0.06)	$ (0.05)	$ (0.08)	$ (0.1)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,299,330)	$ (2,588,013)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt direct write-off and provision	890,576	1,241,159
Depreciation and amortization	557,930	590,618
Stock based compensation	71,427	689,372
Change in fair value of purchase option derivative liability	88,840	(198,751)
Accounts receivable, trade	(833,992)	(2,138,968)
Notes receivable	32,528	(49,387)
Inventories and biological assets	(1,587,645)	(789,355)
Other receivables	(800,686)	(39,756)
Advances to suppliers	(611,849)	958,032
Other current assets	469,985	(180,048)
Long term deposit	18,851	(813,282)
Other noncurrent assets	(139,597)	(106,981)
Accounts payable, trade	(603,967)	2,911,679
Other payables and accrued liabilities	1,305,221	(181,932)
Customer deposits	773,748	308,252
Taxes payable	(253,496)	(133,285)
Net cash used in operating activities	(2,921,456)	(520,646)
CASH FLOWS FROM INVESTING ACTIVITIES:
Disposal of financial assets available for sale	88,897	(73,915)
Purchase of financial assets available for sale	(91,099)
Acquisition of equipment	(142,681)	(212,358)
Increase in construction-in-progress		(473,716)
Increase intangible assets		(298,617)
Investment in a joint venture		(9,387)
Additions to leasehold improvements	(244,047)	(27,986)
Net cash used in investing activities	(388,930)	(1,095,979)
CASH FLOWS FROM FINANCING ACTIVITIES:
Change in restricted cash	(1,947,655)	(503,908)
Proceeds from notes payable	16,177,514	12,664,216
Repayment of notes payable	(18,290,325)	(12,929,115)
Proceeds from equity and debt financing	7,667
Repayment of other payables-related parties	(84,543)	(88,698)
Net cash used in financing activities	(4,137,342)	(857,505)
EFFECT OF EXCHANGE RATE ON CASH	(762,555)	947,579
INCREASE IN CASH	(8,210,283)	(1,526,551)
CASH, beginning of year	15,132,640	18,364,424
CASH, end of year	6,922,357	16,837,873
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes	$ 57,460	$ 42,689

Description of Business and Org

Description of Business and Organization	6 Months Ended
	Sep. 30, 2018
Description of Business and Organization [Abstract]
DESCRIPTION OF BUSINESS AND ORGANIZATION	Note 1 – DESCRIPTION OF BUSINESS AND ORGANIZATION China Jo-Jo Drugstores, Inc. (“Jo-Jo Drugstores” or the “Company”), was incorporated in Nevada on December 19, 2006, originally under the name “Kerrisdale Mining Corporation”. On September 24, 2009, the Company changed its name to “China Jo-Jo Drugstores, Inc.” in connection with a share exchange transaction as described below. On September 17, 2009, the Company completed a share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”), whereby 7,900,000 shares of common stock were issued to the stockholders of Renovation in exchange for 100% of the capital stock of Renovation. The completion of the share exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization and, as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of Renovation (the accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment Management Co., Ltd. (“Jiuxin Management”), Zhejiang Shouantang Medical Technology Co., Ltd. (“Shouantang Technology”), Hangzhou Jiutong Medical Technology Co., Ltd (“Jiutong Medical”), and Hangzhou Jiuyi Medical Technology Co. Ltd. (“Jiuyi Technology”), its wholly-owned subsidiaries. The Company is an online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products in the People’s Republic of China (“China” or the “PRC”). The Company’s offline retail business is comprised primarily of pharmacies, which are operated by Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. (“Jiuzhou Pharmacy”), a company that the Company controls through contractual arrangements. On March 31, 2017, Jiuxin Management established a subsidiary, Lin’An Jiuzhou Pharmacy Co., Ltd (“Lin’An Jiuzhou”) to operates drugstores in Lin’an City. As of September 30, 2018, Jiuzhou Pharmacy has established the following companies, each of which operates a drugstore in Hangzhou City: Entity Name Date Established Hangzhou Jiuben Pharmacy Co., Ltd (“Jiuben Pharmacy”) April 27, 2017 Hangzhou Jiuli Pharmacy Co., Ltd (“Jiuli Pharmacy”) May 22, 2017 Hangzhou Jiuxiang Pharmacy Co., Ltd (“Jiuxiang Pharmacy”) May 26, 2017 Hangzhou Jiuheng Pharmacy Co., Ltd (“Jiuheng Pharmacy”) June 6, 2017 Hangzhou Jiujiu Pharmacy Co., Ltd (“Jiujiu Pharmacy”) June 8, 2017 Hangzhou Jiuyi Pharmacy Co., Ltd (“Jiuyi Pharmacy”) June 8, 2017 Hangzhou Jiuyuan Pharmacy Co., Ltd (“Jiuyuan Pharmacy”) July 13, 2017 Hangzhou Jiumu Pharmacy Co., Ltd (“Jiumu Pharmacy”) July 21, 2017 Hangzhou Jiurui Pharmacy Co., Ltd (“Jiurui Pharmacy”) August 4, 2017 During the six month period ending September 30, 2018, the Company opened two new stores. All of the new stores were without government insurance reimbursement certificates at their openings. The Company’s offline retail business also includes three medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine (“Jiuzhou Clinic”) and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. (“Jiuzhou Service”), both of which are also controlled by the Company through contractual arrangements. On December 18, 2013, Jiuzhou Service established, and held 51% of, Hangzhou Shouantang Health Management Co., Ltd. (“Shouantang Health”), a PRC company licensed to sell health care products. Shouantang Health was closed in April 2015. In May 2016, Hangzhou Shouantang Bio-technology Co., Ltd. (“Shouantang Bio”) set up and held 49% of Hangzhou Kahamadi Bio-technology Co., Ltd.(“Kahamadi Bio”), a joint venture specialized in brand name development for nutritional supplements. The Company currently conducts its online retail pharmacy business through Jiuzhou Pharmacy, which holds the Company’s online pharmacy license. Prior to November 2015, the Company primarily conducted its online retail pharmacy business through Zhejiang Quannuo Internet Technology Co., Ltd.. In May 2015, the Company established Zhejiang Jianshun Network Technology Co. Ltd, a joint venture with Shanghai Jianbao Technology Co., Ltd. (“Jianshun Network”), in order to develop its online pharmaceutical sales from large commercial medical insurance companies. On September 10, 2015, Renovation set up a new entity Jiuyi Technology to provide additional technical support such as webpage development to our online pharmacy business. In November 2015, the Company sold all of the equity interests of Quannou Technology to six individuals for approximately $17,121 (RMB107,074). After the sale, its technical support function has been transferred back to Jiuzhou Pharmacy, which hosts our online pharmacy. The Company’s wholesale business is primarily conducted through Zhejiang Jiuxin Medicine Co., Ltd. (“Jiuxin Medicine”), which is licensed to distribute prescription and non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011. On April 20, 2018, 10% of Jiuxin Medcine shares were sold to Hangzhou Kangzhou Biotech Co. Ltd. for a total proceeds of $79,625 (RMB 507,760), The Company’s herb farming business is conducted by Hangzhou Qianhong Agriculture Development Co., Ltd. (“Qianhong Agriculture”), a wholly-owned subsidiary of Jiuxin Management, which operates a cultivation project of herbal plants used for traditional Chinese medicine (“TCM”). The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities: Entity Name Background Ownership Renovation ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 ● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law ● Registered capital of $14.5 million fully paid 100% Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business 100% Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 ● Registered capital of RMB 5 million fully paid ● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuxin Medicine ● Established in PRC on December 31, 2003 ● Acquired by Jiuzhou Pharmacy in August 2011 ● Registered capital of RMB 10 million fully paid ● Carries out pharmaceutical distribution services VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) Entity Name Background Ownership Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation ● Registered capital of $2.6 million fully paid ● Currently has no operation 100% Jiuben Pharmacy ● Established in the PRC on April 27, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuli Pharmacy ● Established in the PRC on May 22, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuxiang Pharmacy ● Established in the PRC on May 26, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuheng Pharmacy ● Established in the PRC on June 6, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiujiu Pharmacy ● Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuyi Pharmacy ● Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuyuan Pharmacy ● Established in the PRC on July 13, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiumu Pharmacy ● Established in the PRC on July 21, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Entity Name Background Ownership Jiurui Pharmacy ● Established in the PRC on August, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Shouantang Bio ● Established in the PRC in October, 2014 by Shouantang Technology ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name 100% Jiuyi Technology ● Established in the PRC on September 10, 2015 ● 100% held by Renovation ● Technical support to online pharmacy 100% Kahamadi Bio ● Established in the PRC in May 2016 ● 49% held by Shouantang Bio ● Registered capital of RMB 10 million ● Develop brand name for nutritional supplements 49% Lin’An Jiuzhou ● Established in the PRC in March 31, 2017 ● 100% held by Jiuxin Management ● Registered capital of RMB 5 million ● Explore retail pharmacy market in Lin’An City 100% (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu, Mr. Chong’an Jin and Ms. Li Qi, the three shareholders of Renovation (the “Owners”) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.

Liquidity

Liquidity	6 Months Ended
	Sep. 30, 2018
Liquidity [Abstract]
LIQUIDITY	Note 2 – LIQUIDITY Our accounts have been prepared in accordance with U.S. GAAP on a going concern basis. The going concern basis assumes that assets are realized and liabilities are extinguished in the ordinary course of business at amounts disclosed in the financial statements. Our ability to continue as a going concern depends upon aligning our sources of funding (debt and equity) with our expenditure requirements and repayment of the short-term debts as and when they become due. The drug retail business is a highly competitive industry in PRC. Several large drugstore chains and a variety of single stores operate in Hangzhou City and Zhejiang Province. In order to increase our competition advantages and gain more local retail pharmacy market share, during fiscal year 2018, we opened 57 new stores in Hangzhou. As a result, we incurred significant amount of expense related to rental, labor hiring and training, and marketing activities. As the retail pharmaceutical market has become more competitive in recent years, a new store usually cannot make profit in its first year of operation. In fact, we incurred significant expense with limited incremental revenue in the period we opened new stores. As of September 30, 2018, all but 42 of the new stores are without government insurance reimbursement certificates. It usually takes more than one year for a new store to apply for and obtain the local government insurance reimbursement certificate. Historically, sales reimbursed from the government insurance agency contributes more than half of total revenue in a mature store. We are actively in the process of applying certificates for all of our new stores. As more and more new stores obtain certificates, we expect our new store revenue will increase and eventually contribute positive operating cash flow. The Company’s principal sources of liquidity consist of existing cash, equity financing, bank facilities from local banks as well as personal loans from its principal shareholders if necessary. On January 23, 2017, we completed a private placement with a single healthcare-focused institutional investor for the purchase of an aggregate of 4,840,000 of our common stock at a price of $2.20 per share and gross proceeds of approximately $10,648,000. The Company has two credit line agreements from two local banks as displayed in detail in Note 14. Approximately $1.52 million bank credit line was still available for further borrowing as of September 30, 2018. Any borrowing therefrom is guaranteed by a third-party guarantor company, and secured by the Company’s assets pursuant to a collateral agreement, as well as the personal guarantees of some of its principal shareholders. However, in the event the banks withdraw their credit lines with us, or our existing store performance suddenly deteriorate due to unexpected government policy change, or our operating license is canceled as a result of violation of industry regulation, the Company may or may not obtain alternative financing resources to support its continuing operation. At that time, the Company may not be able to continue to present itself on a going concern basis.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and consolidation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation. Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company. Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its suppliers. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs. Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates. Fair value measurements The Company has adopted FASB ASC Topic 820, “Fair Value Measurement and Disclosure,” which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. It does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. It establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets and liabilities, which include financial instruments as defined by FASB ASC 820, include cash and cash equivalents, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 14). The carrying amount of the Company’s derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). As of September 30, 2018, the fair values of our derivative instruments that were carried at fair value (See Note 18). Active Market Observable Unobservable Total Cash and cash equivalents 6,922,357 - $ - 6,922,357 Notes payable - 15,509,129 - 15,509,129 Warrants liability - 227,635 $ - 227,635 Total 6,922,357 15,736,764 $ - 22,659,121 Revenue recognition Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise, such as prescription and OTC drugs, are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows for the return of certain merchandises without reason within seven days after customer’s receipt of the applicable merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal. The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. Restricted cash The Company’s restricted cash consists of cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset. Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company’s retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trends. In the Company’s online pharmacy business, accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. Advances to suppliers Advances to suppliers consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, we have transferred almost all logistics services of our retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only directly purchases certain non-medical products, such as certain nutritional supplements. As a result, almost all advances to suppliers are made by Jiuxin Medicine. Advances to suppliers for our drug wholesale business consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. We typically receive products from vendors within three to nine months after making prepayments. We continuously monitor delivery from, and payments to, our vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues, such as discontinuing of inventory supply, that have been identified. If we have difficulty receiving products from a vendor, we take the following steps: cease purchasing products from such vendor, ask for return of our prepayment promptly, and if necessary, take legal action. If all of these steps are unsuccessful, management then determines whether the prepayments should be reserved or written off. Inventories Inventories are stated at the lower of cost or market value. Cost is determined using the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value. Farmland assets Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold. Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized. Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company’s intangible assets are as follows: Estimated Useful Life Land use rights 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired. Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There were no fixed assets and farmland assets impaired for the three and six months ended September 30, 2018. Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months. Income taxes The Company follows FASB ASC Topic 740,“Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company has adopted FASB ASC Topic 740-10-25, which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax position. The Company must recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company performed a self-assessment and the Company’s liability for income taxes includes liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2018 and March 31, 2018, the management of the Company considered that the Company had no additional liabilities for uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for any uncertain position in the future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the three months ended September 30, 2018 and 2017, respectively. The Company’s tax positions related to open tax years are subject to examination by the relevant tax authorities, the most significant of which is the China Tax Authority. Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products are sold in the PRC and are subject to a VAT on the gross sales price. Since April 2018, The VAT rates have been adjusted to range up to 16%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended September 30, 2018 and 2017. Stock based compensation The Company follows the provisions of FASB ASC 718, “Compensation — Stock Compensation,” which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of FASB ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award. Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $213,382 and $180,639 for the three months ended September 30, 2018 and 2017, respectively, and $405,409 and $320,734 for the six months ended September 30, 2018 and 2017, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities. Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancellable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company’s retail drugstore leases have a 3 to 10 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term. Foreign currency translation The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at September 30, 2018 and at March 31, 2018 were translated at 1 RMB to 0.1456 USD and at 1 RMB to 0.1592 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2018 and 2017 were at 1 RMB to 0.1518 USD and at 1 RMB to 0.1478 USD, respectively. Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to RMB 500,000 (USD 7 5,916) per bank. As of September 30, 2018 and March 31, 2018, the Company had deposits totaling $23,688,866 and $31,433,969 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD 75,916) per bank in PRC will not be covered. To date, the Company has not experienced any losses in such accounts. For the three months ended September 30, 2018, three largest vendors accounted for 56.6% of the Company’s total purchases and one vendor accounted for 23.3% of the Company’s total advances to suppliers. For the three months ended September 30, 2017, three largest vendors accounted for 61.3% of the Company’s total purchases and one vendor accounted for 16.8% of the Company’s total advances to suppliers. For the six months ended September 30, 2018, two vendors accounted for 42.4% of the Company’s total purchases and two vendors accounted for more than 10% of total advances to suppliers. For the six months ended September 30, 2017, the Company’s two largest vendors accounted for 39.6% of the Company’s total purchases and the two largest suppliers accounted for more than 10% of total advances to suppliers. For the three months and six months ended September 30, 2018, no customer accounted for more than 10% of the Company’s total sales and more than 10% of total accounts receivable. For the three months and six months ended September 30, 2017, no customer accounted for more than 10% of the Company’s total sales or more than 10% of total accounts receivable. Recent Accounting Pronouncements In February 2016, the FASB issued No. 2016-02 “Leases (Topic 842): Increasing transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.” The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, for any of the following: 1. A public business entity; 2. A not-for-profit entity that has issued, or is a conduit bond obligor for, securities that are traded, listed, or quoted on an exchange or an over-the-counter market; 3. An employee benefit plan that files financial statements with the U.S. Securities and Exchange Commission (SEC). For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early application of the amendments in this update is permitted for all entities. We are currently evaluating the impact of the adoption of ASU 2016-02 on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-07, “Investments—Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting,” eliminating the requirement to retroactively adopt the equity method of accounting. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments should be applied prospectively upon their effective date to increases in the level of ownership interest or degree of influence that result in the adoption of the equity method. Earlier application is permitted. We are currently evaluating the impact of the adoption of ASU 2016-07 on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” reducing complexity of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. We are currently evaluating the impact of the adoption of ASU 2016-09 on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” providing financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. For public business entities that are U.S. Securities and Exchange Commission (SEC) filers, the amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal ye

Financial Assets Available for

Financial Assets Available for Sale	6 Months Ended
	Sep. 30, 2018
Financial Assets Available for Sale [Abstract]
FINANCIAL ASSETS AVAILABLE FOR SALE	NOTE 4 – FINANCIAL ASSETS AVAILABLE FOR SALE As of September 30, 2018 and March 31, 2018, financial assets available for sale amounted to $162,224 (RMB 1,114,500) and $175,140 (RMB 1,100,000), respectively. In the year ended March 31, 2018, the Company invested a total of $74,890 as a limited partner (LP) in a private equity fund, which is intended to invest in retail pharmaceutical business. The Company has signed an investment agreement with the private equity fund and agreed to invest a total of $295,096 (RMB 2,000,000). Additionally, the Company has signed an investment agreement with Inter Mongolia Songlu Pharmaceutical Co.(“Songlu Pharmaceutical”) and invested a total of $87,334 (RMB600,000), which accounts for 0.5% shares of Songlu Pharmaceutical.

Trade Accounts Receivable

Trade Accounts Receivable	6 Months Ended
	Sep. 30, 2018
Trade Accounts Receivable [Abstract]
TRADE ACCOUNTS RECEIVABLE	NOTE 5 – TRADE ACCOUNTS RECEIVABLE Trade accounts receivable consisted of the following: September 30, March 31, Accounts receivable $ 12,351,161 $ 12,883,707 Less: allowance for doubtful accounts (4,520,448 ) (4,561,314 ) Trade accounts receivable, net $ 7,830,713 $ 8,322,393 For the three months ended September 30, 201 8 and 2017, $33,829 and $98,590 in accounts receivable were directly written off respectively. For the six months ended September 30, 2018 and 2017, $64,412 and $124,983 in accounts receivable were directly written off, respectively. As of September 30, 2018 and March 31, 2018, no trade accounts receivables were pledged as collateral for borrowings from financial institutions.

Other Current Assets

Other Current Assets	6 Months Ended
	Sep. 30, 2018
Other Current Assets [Abstract]
OTHER CURRENT ASSETS	Note 6 – OTHER CURRENT ASSETS Other current assets consisted of the following: September 30, March 31, Prepaid rental expenses (1) $ 1,296,782 $ 1,984,856 Prepaid and other current assets 187,326 131,381 Total $ 1,484,108 $ 2,116,237 (1) Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period.

Property and Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2018
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 7 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: September 30, March 31, Building $ 1,560,683 $ 1,707,145 Leasehold improvements 7,187,866 7,606,496 Farmland development cost 1,740,785 1,904,151 Office equipment and furniture 5,056,136 5,581,554 Motor vehicles 418,519 456,442 Total 15,963,989 17,255,788 Less: Accumulated depreciation (11,133,655 ) (11,905,893 ) Impairment* (2,291,433 ) (2,506,255 ) Property and equipment, net $ 2,538,901 $ 2,843,640 * The variance of impairment from March 31, 2018 to September 30, 2018 is solely caused by exchange rate variance. Depreciation expenses for property and equipment totaled $212,214 and $171,051 for the three months ended September 30, 2018 and 2017, respectively. Depreciation expenses for property and equipment totaled $431,973 and $576,154 for the six months ended September 30, 2018 and 2017, respectively. There were no fixed assets impaired in the three and six months ended September 30, 2018.

Advances to Suppliers

Advances to Suppliers	6 Months Ended
	Sep. 30, 2018
Advances to Suppliers [Abstract]
ADVANCES TO SUPPLIERS	Note 8 – ADVANCES TO SUPPLIERS Advances to suppliers consist of deposits, with or advances to, outside vendors for future inventory purchases. Most of the Company’s suppliers require a certain amount of money to be deposited with them as a guarantee that the Company will receive its purchase on a timely basis. This amount is refundable and bears no interest. As of September 30, 2018 and March 31, 2018, advance to suppliers consist of the following: September 30, March 31, Advance to suppliers* $ 6,533,976 $ 6,505,545 Less: allowance for unrefundable advances (3,299,037 ) (3,058,092 ) Advance to suppliers, net $ 3,234,939 $ 3,447,452 * In order to achieve a larger rebate for certain merchandise, such as colla coril asini (donkey-hide gelatin), from certain suppliers, the Company made a significant cash advance to such suppliers. For the three and six months ended September 30, 2018 and 2017, none of the advances to suppliers were written off against previous allowance for unrefundable advances, respectively.

Inventory

Inventory	6 Months Ended
	Sep. 30, 2018
Inventory [Abstract]
INVENTORY	Note 9 – INVENTORY Inventory consisted of finished goods, valued at $13,799,438 and $13,429,568 as of September 30, 2018 and March 31, 2018, respectively. The Company constantly monitors its potential obsolete products and is allowed to return products close to their expiration dates to its suppliers. Any loss on damaged items is immaterial and will be recognized immediately. As a result, no reserves were made for inventory as of September 30, 2018 and March 31, 2018.

Farmland Assets

Farmland Assets	6 Months Ended
	Sep. 30, 2018
Farmland Assets [Abstract]
FARMLAND ASSETS	Note 10 – FARMLAND ASSETS Farmland assets consist of ginkgo trees planted in 2012 and expected to be harvested and sold in several years. As of September 30, 2018 and March 31, 2018, farmland assets are valued as follows: September 30, March 31, 2018 2018 Farmland assets $ 2,216,471 $ 2,416,839 Less: Impairment* (1,481,520 ) (1,620,553 ) Farmland assets, net $ 734,951 $ 796,286 * The estimated fair value is estimated to be lower than its investment value as of September 30, 2018 and March 31, 2018.

Long Term Deposits, Landlords

Long Term Deposits, Landlords	6 Months Ended
	Sep. 30, 2018
Long Term Deposits, Landlords [Abstract]
LONG TERM DEPOSITS, LANDLORDS	Note 11 – LONG TERM DEPOSITS, LANDLORDS As of September 30, 2018 and March 31, 2018, long term deposits amounted to $2,269,241 and $2,501,968, respectively. Long term deposits are money deposited with, or advanced to, landlords for the purpose of securing retail store leases that the Company does not anticipate being returned within the next twelve months. Most of the Company’s landlords require a minimum payment of nine months’ rent, paid upfront, plus additional deposits.

Other Noncurrent Assets

Other Noncurrent Assets	6 Months Ended
	Sep. 30, 2018
Other Noncurrent Assets [Abstract]
OTHER NONCURRENT ASSETS	Note 12 – OTHER NONCURRENT ASSETS Other noncurrent assets consisted of the following: September 30, March 31, Forest land use rights* $ 1,129,275 $ 1,235,253 Others 150,376 18,099 Total $ 1,279,651 $ 1,253,352 * The prepayment for lease of forest land use rights is a payment made to a local government in connection with entering into an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. The amortization of the prepayment for the lease of forest land use right was approximately $6,579 and $7,042 for the three months ended September 30, 2018 and 2017, respectively.The amortization of the prepayment for the lease of forest land use right was approximately $13,675 and $13,888 for the six months ended September 30, 2018 and 2017, respectively. The Company’s amortizations of the prepayment for lease of land use right for the next five years and thereafter are as follows: For the year ending September 30, Amount 2019 $ 28,529 2020 28,529 2021 28,529 2022 28,529 2023 28,529 Thereafter 986,630

Intangible Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2018
Intangible Assets [Abstract]
INTANGIBLE ASSETS	Note 13 – INTANGIBLE ASSETS Net intangible assets consisted of the following at: September 30, March 31, License (1) $ 1,994,508 $ 1,967,934 SAP software (2) 503,136 764,104 Land use rights (3) 1,419,416 1,552,622 Total intangible assets 3,917,060 4,284,660 Less: accumulated amortization (350,016 ) (228,246 ) Intangible assets, net $ 3,567,044 $ 4,056,414 Amortization expense of intangibles amounted to $87,478 and $7,334 for the three months ended September 30, 2018 and 2017, respectively, and $161,187 and $14,464 for the six months ended September 30, 2018 and 2017, respectively. (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy, a drugstore chain Jiuzhou Pharmacy acquired in 2014. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. The owners of these acquired drugstores agreed to cease their stores’ business and liquidate all of the stores’ accounts before Jiuzhou Pharmacy acquired them. As a result, Jiuzhou Pharmacy has not obtained any assets or liabilities from the stores, but was able to transfer the certificates to our new stores opened at the same time. (2) In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. As of September 30, 2018, the system has been completely installed and running for eight months in the Company. By automatically connecting commodity flow data with accounting recording, the system minimizes the manual errors made by accounting staff. Additionally, the system provides a view of overall and instant cash information by electronically linking local banking systems with SAP. Additional benefits include automatically-generated customized monthly company performance reports, instant inventory monitoring and reporting, and punctual maintenance of customer and supplier accounts. (3) In July 2013, the Company purchased the land use rights of a plot of farmland in Lin’an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’an has not grown, the Company does not expect completion of the plant in the near future.

Notes Payable

Notes Payable	6 Months Ended
	Sep. 30, 2018
Notes Payable [Abstract]
NOTES PAYABLE	Note 14 – NOTES PAYABLE The Company has credit facilities with Hangzhou United Bank (“HUB”), Bank of Hangzhou (“BOH”), and China Merchant Bank (“CMB”) that provided working capital in the form of the following bank acceptance notes at September 30, 2018 and March 31, 2018: Origination Maturity September 30, March 31, Beneficiary Endorser date date 2018 2018 Jiuzhou Pharmacy (1) HUB 10/10/17 04/10/18 2,552,769 Jiuzhou Pharmacy (1) HUB 11/24/17 05/24/18 21,972 Jiuzhou Pharmacy (1) HUB 12/05/17 06/05/18 377,347 Jiuzhou Pharmacy (1) HUB 12/29/17 06/29/18 1,194,135 Jiuzhou Pharmacy (1) HUB 12/29/17 06/29/18 1,443,554 Jiuzhou Pharmacy (1) HUB 02/05/18 08/05/18 2,618,500 Jiuzhou Pharmacy (1) HUB 03/05/18 09/05/18 3,072,638 Jiuzhou Pharmacy (1) HUB 11/06/17 05/06/18 3,553,014 Jiuzhou Pharmacy (1) HUB 12/05/17 06/05/18 1,937,683 Jiuzhou Pharmacy (1) HUB 12/29/17 06/29/18 1,687,711 Jiuzhou Pharmacy (1) HUB 04/09/18 10/09/18 1,502,176 - Jiuzhou Pharmacy (1) HUB 05/04/18 11/04/18 2,167,359 - Jiuzhou Pharmacy (1) HUB 06/29/18 12/29/18 1,860,231 - Jiuzhou Pharmacy (1) HUB 07/05/18 01/05/19 2,993,503 Jiuzhou Pharmacy (1) HUB 08/06/18 02/06/19 1,358,819 Jiuzhou Pharmacy (1) HUB 08/17/18 02/17/19 278,003 Jiuzhou Pharmacy (1) HUB 08/31/18 02/28/19 2,303,019 Jiuzhou Pharmacy (1) HUB 09/05/18 03/05/19 1,878,948 Jiuxin Medicine (2) CMB 02/02/18 08/02/18 71,648 Jiuxin Medicine (2) CMB 02/07/18 08/07/18 95,531 Jiuxin Medicine (2) CMB 03/07/18 09/07/18 538,857 Jiuxin Medicine (2) CMB 03/15/18 09/15/18 44,842 Jiuxin Medicine (2) CMB 04/09/18 10/09/18 282,080 - Jiuxin Medicine (2) CMB 05/14/18 11/14/18 884,991 - Total $ 15,509,129 $ 19,180,200 (1) As of September 30, 2018, the Company had $14,342,058 (RMB 98,531,558) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $14,342,058 (RMB 98,531,558) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $10,206,912 three-year deposit (RMB 70,122,647) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2018, the Company had $18,429,322 (RMB 115,748,985) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $13,565,300 (RMB 85,199,540) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $7,269,509 three-year deposit (RMB 45,657,584) deposited into HUB as a collateral for current and future notes payable from HUB. (2) As of September 30, 2018, the Company had $1,167,071 (RMB 8,017,920) of notes payable from CMB, with restricted cash in the amount of $1,167,072 (RMB 8,017,920) held at the bank. As of March 31, 2018, the Company had $750,878 (RMB 4,716,037) of notes payable from CMB, with restricted cash in the amount of $750,878 (RMB 4,716,037) held at the bank. As of September 30, 2018, the Company had a credit line of approximately $3.64 million in the aggregate from HUB and BOH. By putting up three-year deposit of $10.21 million and the restricted cash of $3.76 million deposited in the banks, the total credit line was $17.61 million. As of September 30, 2018, the Company had approximately $15.51 million of bank notes payable and approximately $2.10 million bank credit line was still available for further borrowing. The bank notes are secured by a shop of Jiuzhou Pharmacy and guaranteed by the Company’s major shareholders.

Taxes

Taxes	6 Months Ended
	Sep. 30, 2018
Taxes [Abstract]
TAXES	Note 15 – TAXES Income tax The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are calculated using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Valuation allowances are provided against deferred income tax assets for amounts which are not considered “more likely than not” to be realized. The Company is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled. Entity Income Tax Jurisdiction Jo-Jo Drugstores United States Renovation Hong Kong, PRC All other entities Mainland, PRC For the three and six months ended September 30, 2018 and 2017, the components of income tax expense consist of the following: For the three months ended For the six months ended September 30, September 30, 2018 2017 2018 2017 Current: Federal - - - - State - - - - Foreign (415 ) 18,047 56,754 38,585 (415 ) 18,047 56,754 38,585 Deferred: Federal - - - - State - - - - Foreign - - - - - - - - Provision for income taxes (415 ) 18,047 56,754 38,585 The following table reconciles the U.S. statutory tax rates with the Company’s effective tax rate for the three and six months ended September 30, 2018 and 2017: For the three months ended For the six months ended September 30, September 30, 2018 2017 2018 2017 U.S. Statutory rates 21.0 % 34.0 % 21.0 % 34.0 % Foreign income not recognized in the U.S. (21.0 ) (34.0 ) (21.0 ) (34.0 ) China income taxes 25.0 25.0 25.0 25.0 Change in valuation allowance (1) (15.5 ) (18.4 ) 8.2 (22.9 ) Non-deductible expenses-permanent difference (2) (9.5 ) (8.2 ) (35.7 ) (3.6 ) Effective tax rate 0.0 % (1.6 )% (2.5 )% (1.5 )% (1) Represents a non-taxable expense due to overall increase in allowance for accounts receivable and advances to suppliers. (2) The (9.5)% and (8.2)% rate adjustments for the three months ended September 30, 2018 and 2017 and the (35.7)% and (3.6)% rate adjustments for the six months ended September 30, 2018 and 2017 represent expenses that primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible for PRC income tax. Jo-Jo Drugstores is incorporated in the U.S. and incurred a net operating loss for income tax purposes for the three and six months ended September 30, 2018 and 2017. As of September 30, 2018, the estimated net operating loss carry forwards for U.S. income tax purposes amounted to $1,503,000, which may be available to reduce future years’ taxable income. These carry forwards will expire if not utilized by 2032. Management believes that the realization of the benefits arising from this loss appears to be uncertain due to the Company’s continuing losses for U.S. income tax purposes. Accordingly, the Company has provided a 100% valuation allowance at September 30, 2018. There was no net change in the valuation allowance for the three and six months ended September 30, 2018 and 2017. Management reviews this valuation allowance periodically and makes adjustments as necessary. The components of the Company’s net deferred tax assets are as follows: As of As of Allowance 679,109 380,025 Long-lived assets impairment - - Depreciation and Amortization 139,483 147,655 Accrued expense 195,760 59,781 Net operating loss carryforward 2,858,926 1,755,691 Foreign Tax Credit Carryover 195,000 195,000 Total deferred tax assets (liabilities): 4,068,277 2,538,152 Valuation allowance (4,068,277 ) (2,538,152 ) Net deferred tax assets (liabilities) - - The Company regularly assesses the realizability of its deferred tax assets and establishes a valuation allowance if it is more-likely-than-not that some portion of the deferred tax assets will not be realized. We weigh all available positive and negative evidence, including earnings history and results of recent operations, scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies. Assumptions used to forecast future taxable income often require significant judgment. More weight is given to objectively verifiable evidence. In the event we determine that we would not be able to realize all or part of our net deferred tax assets in the future, a valuation allowance will be established against deferred tax assets in the period in which we make such determination. The need to establish a valuation allowance against deferred tax assets may cause greater volatility in our effective tax rate. As of September 30, 2018 and September 30, 2017, the estimated net operating loss carry forwards for U.S. income tax purposes amounted to $816,908, which may be available to reduce future years’ taxable income. These carry forwards will expire if not utilized by 2032. In addition, the Company carries a foreign tax credit of $195,000. As of September 30, 2018 and September 30, 2017, the estimated net operating loss carry forwards for Hong Kong income tax purposes amounted to $1,899,812 and $1,713,633, which may be available to reduce future years’ taxable income. As of September 30, 2018 and September 30, 2017, the estimated net operating loss carry forwards for China income tax purposes amounted to $13,553,030 and $7,097,939, which may be available to reduce future years’ taxable income. These carry forwards will expire if not utilized in next five years. On December 22, 2017, the U.S. federal government enacted the 2017 Tax Act. The 2017 Tax Act includes a number of changes in existing tax law impacting businesses, including the transition tax, a one-time deemed repatriation of cumulative undistributed foreign earnings and a permanent reduction in the U.S. federal statutory rate from 35% to 21%, effective on January 1, 2018. ASC 740 requires companies to recognize the effect of tax law changes in the period of enactment, accordingly, the effects must be recognized on companies’ calendar year-end financial statements, even though the effective date for most provisions is January 1, 2018. As a result, we re-measured our net U.S. deferred tax assets at the 21% future tax rate. At December 31, 2017, according to the 2017 Tax Act for estimating our foreign undistributed earnings, we estimated an aggregate deficit in “accumulated earnings and profits,” which is how foreign undistributed earnings are determined for the one-time transition tax and for U.S. income tax purposes. As a result, the one-time transition tax did not have a significant impact on the Company’s FY18 tax provision and there was no undistributed accumulated earnings and profits as of September 30, 2018. In December 2017, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provided a measurement period of up to one year from the enactment date of the 2017 Tax Act for us to complete the accounting for the 2017 Tax Act and its related impacts. The income tax effects of the 2017 Tax Act for which the accounting is incomplete include: the impact of the transition tax, the revaluation of deferred tax assets and liabilities to reflect the 21% corporate tax rate, and the impact to the aforementioned items on state income taxes. We have made reasonable provisional estimates for each of these items, however, these estimates may be affected by other analyses related to the 2017 Tax Act, including but not limited to, any deferred adjustments related to the filing of our fiscal 2018 federal and state income tax returns and further guidance yet to be issued. The Company recorded net unrecognized tax benefits of $0.0 million as of January 31, 2018. It is our policy to classify accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. Audit periods remain open for review until the statute of limitations has passed, which in the PRC, the Company’s most significant tax jurisdiction, is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period.

Postretirement Benefits

Postretirement Benefits	6 Months Ended
	Sep. 30, 2018
Postretirement Benefits [Abstract]
POSTRETIREMENT BENEFITS	Note 16 – POSTRETIREMENT BENEFITS Regulations in the PRC require the Company to contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage of the employee’s current compensation as required by the local government. The Company contributed $346,876 and $276,490 in employment benefits and pension for the three months ended September 30, 2018 and 2017, respectively. The Company contributed $712,512 and $559,734 in employment benefits and pension for the six months ended September 30, 2018 and 2017, respectively.

Related Party Transactions and

Related Party Transactions and Arrangements	6 Months Ended
	Sep. 30, 2018
Related Party Transactions and Arrangements [Abstract]
RELATED PARTY TRANSACTIONS AND ARRANGEMENTS	Note 17 – RELATED PARTY TRANSACTIONS AND ARRANGEMENTS Amounts payable to related parties are summarized as follows: September 30, March 31, Due to a director and CEO (1) 726,670 850,342 Total $ 726,670 $ 850,342 (1) Due to foreign exchange restrictions, the Company’s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. As of September 30, 2018 and March 31, 2018, notes payable totaling $0 and $3,253,630 were secured by the personal properties of certain of the Company’s shareholders, respectively. The lien on such shareholders’ properties has been released since July 2018. The Company leases from Mr. Lei Liu a retail space; the lease expires in September 2018. Rent expenses totaled $4,578 and $4,435 for the three months ended December 31, 2018 and 2017, respectively. Rent expenses totaled $9,110 and $8,870 for the six months ended September 30, 2018 and 2017, respectively. All amounts due and payable have been paid to Mr. Liu as of September 30, 2018.

Warrants

Warrants	6 Months Ended
	Sep. 30, 2018
Warrants [Abstract]
WARRANTS	Note 18 – WARRANTS In connection with the registered direct offering closed on July 19, 2015, the Company issued to an investor a warrant to purchase up to 600,000 shares of common stock at an exercise price of $3.10 per share. The warrant became exercisable on January 19, 2016 and will expire on January 18, 2021. In connection with the offering, the Company also issued a warrant to its placement agent of this offering, pursuant to which the agent may purchase up to 6% of the aggregate number of shares of common stock sold in the offering, i.e. 72,000 shares. Such warrant has the same terms as the warrant issued to investor in the offering. The fair value of the warrants issued to purchase 672,000 shares as described above was estimated by using the binominal pricing model with the following assumptions: Common Stock Common Stock September 30, 2018 (1) March 31, Stock price $ 1.61 $ 1.35 Exercise price $ 3.10 $ 3.10 Annual dividend yield 0 % 0 % Expected term (years) 2.55 2.80 Risk-free interest rate 2.63 % 1.98 % Expected volatility 67.96 % 68.73 % (1) As of September 30, 2018, the warrants had not been exercised. Upon evaluation, the warrants meet the definition of a derivative under FASB ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the warrants was classified as a liability of $138,796 as of March 31, 2018. For the three and six months ended September 30, 2018, the Company recognized a loss of $81,865 and $88,840 for the investor warrant and placement agent warrant, from the change in fair value of the warrant liability. As a result, the warrant liability is carried on the consolidated balance sheets at the fair value of $227,635 for the investor warrant and placement agent warrant, collectively, as of September 30, 2018.

Stockholder's Equity

Stockholder's Equity	6 Months Ended
	Sep. 30, 2018
Stockholder's Equity [Abstract]
STOCKHOLDER'S EQUITY	Note 19 – STOCKHOLDER’S EQUITY Common stock On January 23, 2017, the Company closed a private offering with one institutional investor (the “Investor”) pursuant to which the Company sold to the Investor, and the Investor purchased from the Company, an aggregate of 4,840,000 shares of the common stock, par value $0.001 per share, of the Company, at a purchase price of $2.20 per share, for aggregate gross proceeds to the Company of $10,648,000 (the “Private Placement”). Stock-based compensation The Company accounts for share-based payment awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. Share-based awards are attributed to expenses using the straight-line method over the vesting period. The Company determines the value of each option award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using the Black-Scholes valuation model as permitted under FASB ASC 718 “Compensation - Stock Compensation.” The assumptions used in calculating the fair value of share-based payment awards represent the Company’s best estimates. The Company’s estimates of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates of forfeitures, and the related income tax impact. On March 30, 2018, the Company granted a total of 3,947,100 shares of restricted common stock to its key employees in its retail drugstores and online pharmacy under the Company’s 2010 Equity Incentive Plan, as amended (the “Plan”). The stock awards vested on the grant date. On June 28, 2018, the compensation committee of the Company canceled 225,000 shares granted to the CEO in order to conform aggregate issuances to the 675,000 share limitation set forth in the Plan. The Tax Cuts and Jobs Act of 2017 removed the 162(m) qualified performance based compensation exemption to the $1 million cap on deductions for compensation to covered executives. Section 1.3.2 was in the Plan to permit grants under the Plan to fit within that exemption. As that exemption no longer applies for grants made in 2018 or thereafter, the Plan has been amended to remove the provisions intended to comply with that exemption, including the one in Section 1.3.2. of the Plan. All $5,328,585 expense has been recorded as a service compensation expense in the year ended March 31, 2018. Stock option On November 18, 2014, the Company granted a total of 967,000 shares of stock options under the Plan to a group of a total of 46 grantees including directors, officers and employees. The exercise price of the stock option is $2.50. The option vests on November 18, 2017, provided that the grantees are still employed by the Company on such a date. The options will be exercisable for five years from the vesting date, or November 18, 2017 until November 17, 2022. For the three months ended September 30, 2018 and 2017, $0 and $221,859 was recorded as compensation expense. For the six months ended September 30, 2018 and 2017, $0 and $441,306 was recorded as service compensation expense, respectively. As of September 30, 2018, all compensation costs related to stock option compensation arrangements granted have been recognized. Statutory reserves Statutory reserves represent restricted retained earnings. Based on their legal formation, the Company is required to set aside 10% of its net income as reported in their statutory accounts on an annual basis to the Statutory Surplus Reserve Fund (the “Reserve Fund”). Once the total amount set aside in the Reserve Fund reaches 50% of the entity’s registered capital, further appropriations become discretionary. The Reserve Fund can be used to increase the entity’s registered capital upon approval by relevant government authorities or eliminate its future losses under PRC GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividends or otherwise, except in the event of liquidation. Appropriations to the Reserve Fund are accounted for as a transfer from unrestricted earnings to statutory reserves. During the three and six months ended September 30, 2018 and 2017, the Company did not make appropriations to statutory reserves. There are no legal requirements in the PRC to fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so.

(Loss) Income Per Share

(Loss) Income Per Share	6 Months Ended
	Sep. 30, 2018
(Loss) Income Per Share [Abstract]
(LOSS) INCOME PER SHARE	Note 20 – (LOSS) INCOME PER SHARE The Company reports earnings per share in accordance with the provisions of the FASB’s related accounting standard. This standard requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes dilution, but includes vested restricted stocks and is computed by dividing income available to common stockholders by the weighted average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock. The following is a reconciliation of the basic and diluted (loss) earnings per share computation: Three months ended Six months ended 2018 2017 2018 2017 Net income attributable to controlling interest $ (1,587,417 ) $ (1,168,709 ) $ (2,233,270 ) $ (2,588,013 ) Weighted average shares used in basic computation 28,936,778 25,214,678 28,936,778 25,214,678 Diluted effect of purchase options and warrants - - - - Weighted average shares used in diluted computation 28,936,778 25,214,678 28,936,778 25,214,678 Income per share – Basic: Net (loss) attributable to controlling interest $ (0.06 ) $ (0.05 ) $ (0.08 ) $ (0.10 ) Loss per share – Diluted: Net (loss) attributable to controlling interest $ (0.06 ) $ (0.05 ) $ (0.08 ) $ (0.10 ) For the three and six months ended September 30, 2018, 967,000 shares underlying employee stock options and 600,000 shares underlying outstanding purchase options to an investor, and 72,000 shares underlying outstanding purchase option to an investment placement agent were excluded from the calculation of diluted loss per share as the options were anti-dilutive.

Segments

Segments	6 Months Ended
	Sep. 30, 2018
Segments [Abstract]
SEGMENTS	Note 21 – SEGMENTS The Company operates within four main reportable segments: retail drugstores, online pharmacy, drug wholesale and herb farming. The retail drugstores segment sells prescription and over-the-counter (“OTC”) medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy sells OTC drugs, dietary supplements, medical devices and sundry items to customers through several third-party platforms such as Alibaba’s Tmall, JD.com and Amazon.com, and the Company’s own platform all over China. The drug wholesale segment includes supplying the Company’s own retail drugstores with prescription and OTC medicines, TCM, dietary supplement, medical devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors and hospitals. The Company’s herb farming segment cultivates selected herbs for sales to other drug vendors. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable segments and are included in the retail drugstores segment. The segments’ accounting policies are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest and income taxes not including nonrecurring gains and losses. The Company’s reportable business segments are strategic business units that offer different products and services. Each segment is managed separately because they require different operations and markets to distinct classes of customers. The following table presents summarized information by segment of the continuing operations for the three months ended September 30, 2018. Retail drugstores Online Pharmacy Drug wholesale Herb farming Total Revenue $ 18,136,298 $ 2,122,848 7,149,900 - 27,409,046 Cost of goods 13,277,943 1,909,403 6,424,599 - 21,611,945 Gross profit $ 4,858,355 $ 213,445 725,301 - 5,797,101 Selling expenses 4,156,319 477,348 589,856 - 5,223,523 General and administrative expenses 1,899,147 57,617 258,720 - 2,215,484 (Loss) income from operations $ (1,197,111 ) $ (321,520 ) (123,275 ) - (1,641,906 ) Depreciation and amortization $ 400,295 $ - 1,227 - 401,522 Total capital expenditures $ 216,443 $ - 6 - 216,449 The following table presents summarized information by segment of the continuing operations for the three months ended September 30, 2017. Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 15,047,615 $ 3,065,016 5,378,412 - 23,491,043 Cost of goods 10,804,453 2,665,299 4,463,694 - 17,933,446 Gross profit $ 4,243,162 $ 399,717 914,718 - 5,557,597 Selling expenses 2,582,089 459,785 1,308,898 - 4,350,772 General and administrative expenses 2,742,437 107,616 5,361 141 2,855,555 (Loss) income from operations $ (1,081,364 ) $ (167,684 ) (399,541 ) (141 ) (1,648,730 ) Depreciation and amortization $ (416,231 ) $ - 121,767 (119,461 ) (413,925 ) Total capital expenditures $ 149,568 $ - 45,451 - 195,019 The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2018: Retail Online Drug Herb Total Revenue $ 34,104,639 $ 4,144,717 11,932,256 50,181,612 Cost of goods 24,441,166 3,650,307 10,676,235 38,767,708 Gross profit $ 9,663,473 $ 494,410 1,256,021 11,413,904 Selling expenses 7,633,996 878,710 1,337,795 9,850,501 General and administrative expenses 3,200,615 244,841 324,556 3,770,012 (Loss) income from operations $ (1,171,138 ) $ (629,141 ) 406,330 (2,206,609 ) Depreciation and amortization $ 530,952 $ - 7,013 537,965 Total capital expenditures $ 373,715 $ - 1,123 374,838 The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2017: Retail Online Drug Herb Total Revenue $ 28,067,985 $ 6,200,705 10,892,721 45,161,411 Cost of goods 20,540,661 5,509,797 9,375,695 35,426,153 Gross profit $ 7,527,324 $ 690,908 1,517,026 9,735,258 Selling expenses 5,001,645 975,172 2,290,814 8,267,631 General and administrative expenses 4,012,213 177,905 380,833 10,047 4,580,998 (Loss) income from operations $ (1,486,534 ) $ (462,169 ) (1,154,621 ) (10,047 ) (3,113,371 ) Depreciation and amortization $ (329,242 ) $ - 204,374 (124,868 ) Total capital expenditures $ 206,142 $ - 6,216 212,358 The Company does not have long-lived assets located outside the PRC. In accordance with the enterprise-wide disclosure requirements of FASB’s accounting standard, the Company’s net revenue from external customers through its retail drugstores by main product category is as follows: Three months ended Six months ended 2018 2017 2018 2017 Prescription drugs $ 5,270,412 $ 4,891,435 $ 11,079,627 $ 9,486,789 OTC drugs 7,660,287 6,780,715 14,625,115 12,424,677 Nutritional supplements 1,935,456 1,638,031 2,880,662 2,675,363 TCM 1,689,697 938,688 3,272,265 1,951,199 Sundry products 345,964 362,443 550,825 624,479 Medical devices 1,234,482 436,303 1,696,145 905,478 Total $ 18,136,298 $ 15,047,615 $ 34,104,639 $ 28,067,985 The Company’s net revenue from external customers through online pharmacy by main product category is as follows: Three months ended Six months ended 2018 2017 2018 2017 Prescription drugs $ - $ - $ - $ - OTC drugs 798,938 1,385,899 1,574,931 2,503,291 Nutritional supplements 211,990 334,806 355,086 850,882 TCM 20,703 10,182 25,632 10,182 Sundry products 517,123 422,388 1,554,289 841,421 Medical devices 574,094 911,741 634,779 1,994,929 Total $ 2,122,848 $ 3,065,016 $ 4,144,717 $ 6,200,705 The Company’s net revenue from external customers through wholesale by main product category is as follows: Three months ended Six months ended 2018 2017 2018 2017 Prescription drugs $ 4,355,706 $ 3,077,232 $ 7,775,242 $ 6,474,633 OTC drugs 2,629,761 2,248,503 3,904,680 4,349,153 Nutritional supplements 48,216 12,279 73,597 28,537 TCM 57,458 604 79,309 604 Sundry products 10,775 - 15,530 - Medical devices 47,984 39,794 83,898 39,794 Total $ 7,149,900 $ 5,378,412 $ 11,932,256 $ 10,892,721

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2018
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 22 – COMMITMENTS AND CONTINGENCIES Operating lease commitments The Company recognizes lease expenses on a straight line basis over the term of its leases in accordance with the relevant accounting standards. The Company has entered into various tenancy agreements for its store premises and for the land leased from a local government to farm herbs. The Company’s commitments for minimum rental payments under its leases for the next five years and thereafter are as follows: Periods ending September 30, Retail Online Drug Herb Total 2019 $ 4,363,685 $ - $ - $ - $ 4,363,685 2020 3,592,727 - - - 3,592,727 2021 2,835,408 - - - 2,835,408 2022 2,199,735 - - - 2,199,735 2023 1,440,756 - - - 1,440,756 Thereafter 2,063,945 - - - 2,063,945 Total rent expense amounted to $1,155,529 and $1,076,749 for the three months ended September 30, 2018 and 2017, respectively. Total rent expense amounted to $2,310,622 and $1,887,461 for the six months ended September 30, 2018 and 2017, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 23 – SUBSEQUENT EVENTS On October 9, 2018, Jiuxin Medicine signed a new credit line agreement with Hangzhou United Bank for a credit line up to $5,094,530 (RMB 35,000,000) for a period from October 9, 2018 to October 8, 2020. Jiuzhou Pharmacy and a third-party company act as guarantors of any borrowing within the credit line.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.
Consolidation of variable interest entities	Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company.
Risks and Uncertainties	Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its suppliers. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs.
Use of estimates	Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.
Fair value measurements	Fair value measurements The Company has adopted FASB ASC Topic 820, “Fair Value Measurement and Disclosure,” which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. It does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. It establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets and liabilities, which include financial instruments as defined by FASB ASC 820, include cash and cash equivalents, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 14). The carrying amount of the Company’s derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). As of September 30, 2018, the fair values of our derivative instruments that were carried at fair value (See Note 18). Active Market Observable Unobservable Total Cash and cash equivalents 6,922,357 - $ - 6,922,357 Notes payable - 15,509,129 - 15,509,129 Warrants liability - 227,635 $ - 227,635 Total 6,922,357 15,736,764 $ - 22,659,121
Revenue recognition	Revenue recognition Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise, such as prescription and OTC drugs, are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows for the return of certain merchandises without reason within seven days after customer’s receipt of the applicable merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal. The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.
Restricted cash	Restricted cash The Company’s restricted cash consists of cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.
Accounts receivable	Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company’s retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trends. In the Company’s online pharmacy business, accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate.
Advances to suppliers	Advances to suppliers Advances to suppliers consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, we have transferred almost all logistics services of our retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only directly purchases certain non-medical products, such as certain nutritional supplements. As a result, almost all advances to suppliers are made by Jiuxin Medicine. Advances to suppliers for our drug wholesale business consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. We typically receive products from vendors within three to nine months after making prepayments. We continuously monitor delivery from, and payments to, our vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues, such as discontinuing of inventory supply, that have been identified. If we have difficulty receiving products from a vendor, we take the following steps: cease purchasing products from such vendor, ask for return of our prepayment promptly, and if necessary, take legal action. If all of these steps are unsuccessful, management then determines whether the prepayments should be reserved or written off.
Inventories	Inventories Inventories are stated at the lower of cost or market value. Cost is determined using the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value.
Farmland assets	Farmland assets Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold.
Property and equipment	Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized.
Intangible assets	Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company’s intangible assets are as follows: Estimated Useful Life Land use rights 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired.
Impairment of long lived assets	Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There were no fixed assets and farmland assets impaired for the three and six months ended September 30, 2018.
Notes payable	Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months.
Income taxes	Income taxes The Company follows FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company has adopted FASB ASC Topic 740-10-25, which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax position. The Company must recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company performed a self-assessment and the Company’s liability for income taxes includes liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2018 and March 31, 2018, the management of the Company considered that the Company had no additional liabilities for uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for any uncertain position in the future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the three months ended September 30, 2018 and 2017, respectively. The Company’s tax positions related to open tax years are subject to examination by the relevant tax authorities, the most significant of which is the China Tax Authority.
Value added tax	Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products are sold in the PRC and are subject to a VAT on the gross sales price. Since April 2018, The VAT rates have been adjusted to range up to 16%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended September 30, 2018 and 2017.
Stock based compensation	Stock based compensation The Company follows the provisions of FASB ASC 718, “Compensation — Stock Compensation,” which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of FASB ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award.
Advertising and promotion costs	Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $213,382 and $180,639 for the three months ended September 30, 2018 and 2017, respectively, and $405,409 and $320,734 for the six months ended September 30, 2018 and 2017, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities.
Operating leases	Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancellable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company’s retail drugstore leases have a 3 to 10 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term.
Foreign currency translation	Foreign currency translation The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at September 30, 2018 and at March 31, 2018 were translated at 1 RMB to 0.1456 USD and at 1 RMB to 0.1592 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2018 and 2017 were at 1 RMB to 0.1518 USD and at 1 RMB to 0.1478 USD, respectively.
Concentrations and credit risk	Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to RMB 500,000 (USD 7 5,916) per bank. As of September 30, 2018 and March 31, 2018, the Company had deposits totaling $23,688,866 and $31,433,969 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD 75,916) per bank in PRC will not be covered. To date, the Company has not experienced any losses in such accounts. For the three months ended September 30, 2018, three largest vendors accounted for 56.6% of the Company’s total purchases and one vendor accounted for 23.3% of the Company’s total advances to suppliers. For the three months ended September 30, 2017, three largest vendors accounted for 61.3% of the Company’s total purchases and one vendor accounted for 16.8% of the Company’s total advances to suppliers. For the six months ended September 30, 2018, two vendors accounted for 42.4% of the Company’s total purchases and two vendors accounted for more than 10% of total advances to suppliers. For the six months ended September 30, 2017, the Company’s two largest vendors accounted for 39.6% of the Company’s total purchases and the two largest suppliers accounted for more than 10% of total advances to suppliers. For the three months and six months ended September 30, 2018, no customer accounted for more than 10% of the Company’s total sales and more than 10% of total accounts receivable. For the three months and six months ended September 30, 2017, no customer accounted for more than 10% of the Company’s total sales or more than 10% of total accounts receivable.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued No. 2016-02 “Leases (Topic 842): Increasing transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.” The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, for any of the following: 1. A public business entity; 2. A not-for-profit entity that has issued, or is a conduit bond obligor for, securities that are traded, listed, or quoted on an exchange or an over-the-counter market; 3. An employee benefit plan that files financial statements with the U.S. Securities and Exchange Commission (SEC). For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early application of the amendments in this update is permitted for all entities. We are currently evaluating the impact of the adoption of ASU 2016-02 on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-07, “Investments—Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting,” eliminating the requirement to retroactively adopt the equity method of accounting. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments should be applied prospectively upon their effective date to increases in the level of ownership interest or degree of influence that result in the adoption of the equity method. Earlier application is permitted. We are currently evaluating the impact of the adoption of ASU 2016-07 on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” reducing complexity of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. We are currently evaluating the impact of the adoption of ASU 2016-09 on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” providing financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. For public business entities that are U.S. Securities and Exchange Commission (SEC) filers, the amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All entities may adopt the amendments in this update earlier as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230):Classification of Certain Cash Receipts and Cash Payments,” addressing eight specific cash flow issues with the objective of reducing the existing diversity in practice. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. The amendments in this update should be applied using a retrospective transition method to each period presented. If it is impracticable to apply the amendments retrospectively for some of the issues, the amendments for those issues would be applied prospectively as of the earliest date practicable. We are currently evaluating the impact of the adoption of ASU 2016-15 on our consolidated financial statements. In August 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230):Restricted Cash,” addressing that diversity. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in this update should be applied using a retrospective transition method to each period presented. We are currently evaluating the impact of the adoption of ASU 2016-18 on our consolidated financial statements. In July 2017, the FASB issued Accounting Standards update (“ASU”) No. 2017-11, “Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception”. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. We are currently evaluating the impact of the adoption of ASU 2017-11 on our consolidated financial statements. In January 2017, the FASB issued Accounting Standards update (“ASU”) No. 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which removes Step 2 from the goodwill impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit’s carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. Public business entity that is a U.S. Securities and Exchange Commission filer should adopt the amendments in this ASU for its annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact of the adoption of ASU 2017-04 on our consolidated financial statements. Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08,“Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net),” which amends the principal versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, “Identifying Performance Obligations and Licensing,” which amends the guidance in those areas in the new revenue recognition standard. On April 1, 2018, we adopted the guidance in ASC 606 and all the related amendments and applied the new revenue standard to all contracts using the modified retrospective method. Based on the new standard our revenue recognition policies related to membership rewards programs will change. But the impact of the new revenue standard was not material and there was no adjustment required to the opening balance of retained earnings. We expect the impact of the adoption of the new revenue standard to be immaterial to our net income on an ongoing basis. The following is a discussion of the Company’s revenue recognition policies by segment under the new revenue recognition accounting standard: Pharmacy retail sales The physical pharmacies sell prescription drugs, OTC drugs, traditional Chinese medicine, nutritional supplements, medical devices and sundry products. Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise, such as prescription and OTC drugs, are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. As revenue from medical services are minimal compared to pharmacy retail sales, it is included as part of the pharmacy retail sales. Online pharmacy sales The online pharmacy sells various health products except for prescription drugs. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows for the return of certain merchandises without reason within seven days after customer’s receipt of the applicable merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Wholesale Jiuxin Medicine purchases medicine in quantity and distributes products primarily to local pharmacies and medical products dealers. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal. The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. Disaggregation of Revenue The following table disaggregates the Company’s revenue by major source in each segment for the three and six months ended September 30, 2018: Three months ended September 30 2018 2017 Retail drugstores Prescription drugs $ 5,270,412 $ 4,891,435 OTC drugs 7,660,287 6,780,715 Nutritional supplements 1,935,456 1,638,031 TCM 1,689,697 938,688 Sundry products 345,964 362,443 Medical devices 1,234,482 436,303 Total retail revenue $ 18,136,298 $ 15,047,615 Online pharmacy Prescription drugs $ - $ - OTC drugs 798,938 1,385,899 Nutritional supplements 211,990 334,806 TCM 20,703 10,182 Sundry products 517,123 422,388 Medical devices 574,094 911,741 Total online revenue $ 2,122,848 $ 3,065,016 Drug wholesale Prescription drugs $ 4,355,706 $ 3,077,232 OTC drugs 2,629,761 2,248,503 Nutritional supplements 48,216 12,279 TCM 57,458 604 Sundry products 10,775 - Medical devices 47,984 39,794 Total wholesale revenue $ 7,149,900 $ 5,378,412 Total revenue $ 27,409,046 $ 23,491,043 Six months ended September 30 2018 2017 Retail drugstores Prescription drugs $ 11,079,627 $ 9,486,789 OTC drugs 14,625,115 12,424,677 Nutritional supplements 2,880,662 2,675,363 TCM 3,272,265 1,951,199 Sundry products 550,825 624,479 Medical devices 1,696,145 905,478 Total retail revenue $ 34,104,639 $ 28,067,985 Online pharmacy Prescription drugs $ - $ - OTC drugs 1,574,931 2,503,291 Nutritional supplements 355,086 850,882 TCM 25,632 10,182 Sundry products 1,554,289 841,421 Medical devices 634,779 1,994,929 Total online revenue $ 4,144,717 $ 6,200,705 Drug wholesale Prescription drugs $ 7,775,242 $ 6,474,633 OTC drugs 3,904,680 4,349,153 Nutritional supplements 73,597 28,537 TCM 79,309 604 Sundry products 15,530 - Medical devices 83,898 39,794 Total wholesale revenue $ 11,932,256 $ 10,892,721 Total revenue $ 50,181,612 $ 45,161,411 Contract Balances Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, for example membership points. The consideration received remains a contract liability until goods or services have been provided to the retail customer. The following table provides information about receivables and contract liabilities from contracts with customers: September 30, March 31, Trade receivable(included in accounts receivable, net) $ 7,830,713 $ 8,322,393 Contract liabilities (included in accrued expenses) 5,176,002 4,461,136 Impact of New Revenue Recognition Standard on Financial Statement Line Items The Company adopted ASU 2014-09 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts was recorded as an adjustment to retained earnings as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the condensed statement of operation for the six months ended September 30, 2018: Impact of Change in Accounting Policy As Reported Balances For the Three Months Balance Ended without In thousands September 30, Adjustments Adoption of Condensed Consolidated Statement of Operations: Net revenues 27,409 (37 ) 27,372 Cost of revenues 21,612 - 21,612 Gross profit 5,797 (37 ) 5,760 SELLING EXPENSES 5,224 37 5,187 GENERAL AND ADMINISTRATIVE EXPENSES 2,215 - 2,215 Operating profit (1,642 ) - (1,642 ) Income (loss) before income tax provision (1,603 ) - (2,243 ) Income tax provision - - - Income (loss) from continuing operations (1,603 ) - (1,603 ) Net income (loss) (1,603 ) - (1,603 ) Impact of Change in Accounting Policy As Reported Balances For the Six Months Balance Ended without In thousands September 30, Adjustments Adoption of Condensed Consolidated Statement of Operations: Net revenues 50,182 144 50,326 Cost of revenues 38,768 - 38,768 Gross profit 11,414 144 11,558 SELLING EXPENSES 9,851 (144 ) 9,995 GENERAL AND ADMINISTRATIVE EXPENSES 3,770 - 3,770 Operating profit (2,207 ) - (2,207 ) Income (loss) before income tax provision (2,243 ) - (2,243 ) Income tax provision 57 - 57 Income (loss) from continuing operations (2,299 ) - (2,299 ) Net income (loss) (2,299 ) - (2,299 ) The adoption of ASU 2014-09 has no effect on consolidated balance sheet and statement of cash flow.

Description of Business and O_2

Description of Business and Organization (Tables)	6 Months Ended
	Sep. 30, 2018
Description of Business and Organization [Abstract]
Schedule of subsidiaries	Entity Name Date Established Hangzhou Jiuben Pharmacy Co., Ltd (“Jiuben Pharmacy”) April 27, 2017 Hangzhou Jiuli Pharmacy Co., Ltd (“Jiuli Pharmacy”) May 22, 2017 Hangzhou Jiuxiang Pharmacy Co., Ltd (“Jiuxiang Pharmacy”) May 26, 2017 Hangzhou Jiuheng Pharmacy Co., Ltd (“Jiuheng Pharmacy”) June 6, 2017 Hangzhou Jiujiu Pharmacy Co., Ltd (“Jiujiu Pharmacy”) June 8, 2017 Hangzhou Jiuyi Pharmacy Co., Ltd (“Jiuyi Pharmacy”) June 8, 2017 Hangzhou Jiuyuan Pharmacy Co., Ltd (“Jiuyuan Pharmacy”) July 13, 2017 Hangzhou Jiumu Pharmacy Co., Ltd (“Jiumu Pharmacy”) July 21, 2017 Hangzhou Jiurui Pharmacy Co., Ltd (“Jiurui Pharmacy”) August 4, 2017
Schedule of consolidated financial statements activities	Entity Name Background Ownership Renovation ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 ● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law ● Registered capital of $14.5 million fully paid 100% Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business 100% Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 ● Registered capital of RMB 5 million fully paid ● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuxin Medicine ● Established in PRC on December 31, 2003 ● Acquired by Jiuzhou Pharmacy in August 2011 ● Registered capital of RMB 10 million fully paid ● Carries out pharmaceutical distribution services VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) Entity Name Background Ownership Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation ● Registered capital of $2.6 million fully paid ● Currently has no operation 100% Jiuben Pharmacy ● Established in the PRC on April 27, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuli Pharmacy ● Established in the PRC on May 22, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuxiang Pharmacy ● Established in the PRC on May 26, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuheng Pharmacy ● Established in the PRC on June 6, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiujiu Pharmacy ● Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuyi Pharmacy ● Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiuyuan Pharmacy ● Established in the PRC on July 13, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiumu Pharmacy ● Established in the PRC on July 21, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Entity Name Background Ownership Jiurui Pharmacy ● Established in the PRC on August, 2017 by Jiuzhou Pharmacy ● Registered capital of $15,920 fully paid ● Operates a pharmacy in Hangzhou VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Shouantang Bio ● Established in the PRC in October, 2014 by Shouantang Technology ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name 100% Jiuyi Technology ● Established in the PRC on September 10, 2015 ● 100% held by Renovation ● Technical support to online pharmacy 100% Kahamadi Bio ● Established in the PRC in May 2016 ● 49% held by Shouantang Bio ● Registered capital of RMB 10 million ● Develop brand name for nutritional supplements 49% Lin’An Jiuzhou ● Established in the PRC in March 31, 2017 ● 100% held by Jiuxin Management ● Registered capital of RMB 5 million ● Explore retail pharmacy market in Lin’An City 100% (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu, Mr. Chong’an Jin and Ms. Li Qi, the three shareholders of Renovation (the “Owners”) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Schedule of fair values of derivative instruments	Active Market Observable Unobservable Total Cash and cash equivalents 6,922,357 - $ - 6,922,357 Notes payable - 15,509,129 - 15,509,129 Warrants liability - 227,635 $ - 227,635 Total 6,922,357 15,736,764 $ - 22,659,121
Schedule of estimated useful lives of property and equipment	Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years
Schedule of estimated useful lives of intangible assets	Estimated Useful Life Land use rights 50 years Software 3 years
Schedule of revenue by major source in each segment	Three months ended September 30 2018 2017 Retail drugstores Prescription drugs $ 5,270,412 $ 4,891,435 OTC drugs 7,660,287 6,780,715 Nutritional supplements 1,935,456 1,638,031 TCM 1,689,697 938,688 Sundry products 345,964 362,443 Medical devices 1,234,482 436,303 Total retail revenue $ 18,136,298 $ 15,047,615 Online pharmacy Prescription drugs $ - $ - OTC drugs 798,938 1,385,899 Nutritional supplements 211,990 334,806 TCM 20,703 10,182 Sundry products 517,123 422,388 Medical devices 574,094 911,741 Total online revenue $ 2,122,848 $ 3,065,016 Drug wholesale Prescription drugs $ 4,355,706 $ 3,077,232 OTC drugs 2,629,761 2,248,503 Nutritional supplements 48,216 12,279 TCM 57,458 604 Sundry products 10,775 - Medical devices 47,984 39,794 Total wholesale revenue $ 7,149,900 $ 5,378,412 Total revenue $ 27,409,046 $ 23,491,043 Six months ended September 30 2018 2017 Retail drugstores Prescription drugs $ 11,079,627 $ 9,486,789 OTC drugs 14,625,115 12,424,677 Nutritional supplements 2,880,662 2,675,363 TCM 3,272,265 1,951,199 Sundry products 550,825 624,479 Medical devices 1,696,145 905,478 Total retail revenue $ 34,104,639 $ 28,067,985 Online pharmacy Prescription drugs $ - $ - OTC drugs 1,574,931 2,503,291 Nutritional supplements 355,086 850,882 TCM 25,632 10,182 Sundry products 1,554,289 841,421 Medical devices 634,779 1,994,929 Total online revenue $ 4,144,717 $ 6,200,705 Drug wholesale Prescription drugs $ 7,775,242 $ 6,474,633 OTC drugs 3,904,680 4,349,153 Nutritional supplements 73,597 28,537 TCM 79,309 604 Sundry products 15,530 - Medical devices 83,898 39,794 Total wholesale revenue $ 11,932,256 $ 10,892,721 Total revenue $ 50,181,612 $ 45,161,411
Schedule of receivables and contract liabilities from contracts with customers	September 30, March 31, Trade receivable(included in accounts receivable, net) $ 7,830,713 $ 8,322,393 Contract liabilities (included in accrued expenses) 5,176,002 4,461,136
Schedule of condensed statement of operation	Impact of Change in Accounting Policy As Reported Balances For the Three Months Balance Ended without In thousands September 30, Adjustments Adoption of Condensed Consolidated Statement of Operations: Net revenues 27,409 (37 ) 27,372 Cost of revenues 21,612 - 21,612 Gross profit 5,797 (37 ) 5,760 SELLING EXPENSES 5,224 37 5,187 GENERAL AND ADMINISTRATIVE EXPENSES 2,215 - 2,215 Operating profit (1,642 ) - (1,642 ) Income (loss) before income tax provision (1,603 ) - (2,243 ) Income tax provision - - - Income (loss) from continuing operations (1,603 ) - (1,603 ) Net income (loss) (1,603 ) - (1,603 ) Impact of Change in Accounting Policy As Reported Balances For the Six Months Balance Ended without In thousands September 30, Adjustments Adoption of Condensed Consolidated Statement of Operations: Net revenues 50,182 144 50,326 Cost of revenues 38,768 - 38,768 Gross profit 11,414 144 11,558 SELLING EXPENSES 9,851 (144 ) 9,995 GENERAL AND ADMINISTRATIVE EXPENSES 3,770 - 3,770 Operating profit (2,207 ) - (2,207 ) Income (loss) before income tax provision (2,243 ) - (2,243 ) Income tax provision 57 - 57 Income (loss) from continuing operations (2,299 ) - (2,299 ) Net income (loss) (2,299 ) - (2,299 )

Trade Accounts Receivable (Tabl

Trade Accounts Receivable (Tables)	6 Months Ended
	Sep. 30, 2018
Trade Accounts Receivable [Abstract]
Schedule of trade accounts receivable	September 30, March 31, Accounts receivable $ 12,351,161 $ 12,883,707 Less: allowance for doubtful accounts (4,520,448 ) (4,561,314 ) Trade accounts receivable, net $ 7,830,713 $ 8,322,393

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Sep. 30, 2018
Other Current Assets [Abstract]
Schedule of other current assets	September 30, March 31, Prepaid rental expenses (1) $ 1,296,782 $ 1,984,856 Prepaid and other current assets 187,326 131,381 Total $ 1,484,108 $ 2,116,237 (1) Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Sep. 30, 2018
Property and Equipment [Abstract]
Schedule of property and equipment	September 30, March 31, Building $ 1,560,683 $ 1,707,145 Leasehold improvements 7,187,866 7,606,496 Farmland development cost 1,740,785 1,904,151 Office equipment and furniture 5,056,136 5,581,554 Motor vehicles 418,519 456,442 Total 15,963,989 17,255,788 Less: Accumulated depreciation (11,133,655 ) (11,905,893 ) Impairment* (2,291,433 ) (2,506,255 ) Property and equipment, net $ 2,538,901 $ 2,843,640 * The variance of impairment from March 31, 2018 to September 30, 2018 is solely caused by exchange rate variance.

Advances to Suppliers (Tables)

Advances to Suppliers (Tables)	6 Months Ended
	Sep. 30, 2018
Advances to Suppliers [Abstract]
Schedule of advance to suppliers	September 30, March 31, Advance to suppliers* $ 6,533,976 $ 6,505,545 Less: allowance for unrefundable advances (3,299,037 ) (3,058,092 ) Advance to suppliers, net $ 3,234,939 $ 3,447,452 * In order to achieve a larger rebate for certain merchandise, such as colla coril asini (donkey-hide gelatin), from certain suppliers, the Company made a significant cash advance to such suppliers.

Farmland Assets (Tables)

Farmland Assets (Tables)	6 Months Ended
	Sep. 30, 2018
Farmland Assets [Abstract]
Schedule of farmland assets	September 30, March 31, 2018 2018 Farmland assets $ 2,216,471 $ 2,416,839 Less: Impairment* (1,481,520 ) (1,620,553 ) Farmland assets, net $ 734,951 $ 796,286 * The estimated fair value is estimated to be lower than its investment value as of September 30, 2018 and March 31, 2018.

Other Noncurrent Assets (Tables

Other Noncurrent Assets (Tables)	6 Months Ended
	Sep. 30, 2018
Other Noncurrent Assets [Abstract]
Schedule of other noncurrent assets	September 30, March 31, Forest land use rights* $ 1,129,275 $ 1,235,253 Others 150,376 18,099 Total $ 1,279,651 $ 1,253,352 * The prepayment for lease of forest land use rights is a payment made to a local government in connection with entering into an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060.
Schedule of amortizations of the prepayment for lease of land use right	For the year ending September 30, Amount 2019 $ 28,529 2020 28,529 2021 28,529 2022 28,529 2023 28,529 Thereafter 986,630

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2018
Intangible Assets [Abstract]
Schedule of net intangible assets	September 30, March 31, License (1) $ 1,994,508 $ 1,967,934 SAP software (2) 503,136 764,104 Land use rights (3) 1,419,416 1,552,622 Total intangible assets 3,917,060 4,284,660 Less: accumulated amortization (350,016 ) (228,246 ) Intangible assets, net $ 3,567,044 $ 4,056,414 (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy, a drugstore chain Jiuzhou Pharmacy acquired in 2014. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. The owners of these acquired drugstores agreed to cease their stores’ business and liquidate all of the stores’ accounts before Jiuzhou Pharmacy acquired them. As a result, Jiuzhou Pharmacy has not obtained any assets or liabilities from the stores, but was able to transfer the certificates to our new stores opened at the same time. (2) In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. As of September 30, 2018, the system has been completely installed and running for eight months in the Company. By automatically connecting commodity flow data with accounting recording, the system minimizes the manual errors made by accounting staff. Additionally, the system provides a view of overall and instant cash information by electronically linking local banking systems with SAP. Additional benefits include automatically-generated customized monthly company performance reports, instant inventory monitoring and reporting, and punctual maintenance of customer and supplier accounts. (3) In July 2013, the Company purchased the land use rights of a plot of farmland in Lin’an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’an has not grown, the Company does not expect completion of the plant in the near future.

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Sep. 30, 2018
Notes Payable [Abstract]
Schedule of credit facilities with banks	Origination Maturity September 30, March 31, Beneficiary Endorser date date 2018 2018 Jiuzhou Pharmacy (1) HUB 10/10/17 04/10/18 2,552,769 Jiuzhou Pharmacy (1) HUB 11/24/17 05/24/18 21,972 Jiuzhou Pharmacy (1) HUB 12/05/17 06/05/18 377,347 Jiuzhou Pharmacy (1) HUB 12/29/17 06/29/18 1,194,135 Jiuzhou Pharmacy (1) HUB 12/29/17 06/29/18 1,443,554 Jiuzhou Pharmacy (1) HUB 02/05/18 08/05/18 2,618,500 Jiuzhou Pharmacy (1) HUB 03/05/18 09/05/18 3,072,638 Jiuzhou Pharmacy (1) HUB 11/06/17 05/06/18 3,553,014 Jiuzhou Pharmacy (1) HUB 12/05/17 06/05/18 1,937,683 Jiuzhou Pharmacy (1) HUB 12/29/17 06/29/18 1,687,711 Jiuzhou Pharmacy (1) HUB 04/09/18 10/09/18 1,502,176 - Jiuzhou Pharmacy (1) HUB 05/04/18 11/04/18 2,167,359 - Jiuzhou Pharmacy (1) HUB 06/29/18 12/29/18 1,860,231 - Jiuzhou Pharmacy (1) HUB 07/05/18 01/05/19 2,993,503 Jiuzhou Pharmacy (1) HUB 08/06/18 02/06/19 1,358,819 Jiuzhou Pharmacy (1) HUB 08/17/18 02/17/19 278,003 Jiuzhou Pharmacy (1) HUB 08/31/18 02/28/19 2,303,019 Jiuzhou Pharmacy (1) HUB 09/05/18 03/05/19 1,878,948 Jiuxin Medicine (2) CMB 02/02/18 08/02/18 71,648 Jiuxin Medicine (2) CMB 02/07/18 08/07/18 95,531 Jiuxin Medicine (2) CMB 03/07/18 09/07/18 538,857 Jiuxin Medicine (2) CMB 03/15/18 09/15/18 44,842 Jiuxin Medicine (2) CMB 04/09/18 10/09/18 282,080 - Jiuxin Medicine (2) CMB 05/14/18 11/14/18 884,991 - Total $ 15,509,129 $ 19,180,200 (1) As of September 30, 2018, the Company had $14,342,058 (RMB 98,531,558) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $14,342,058 (RMB 98,531,558) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $10,206,912 three-year deposit (RMB 70,122,647) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2018, the Company had $18,429,322 (RMB 115,748,985) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $13,565,300 (RMB 85,199,540) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $7,269,509 three-year deposit (RMB 45,657,584) deposited into HUB as a collateral for current and future notes payable from HUB. (2) As of September 30, 2018, the Company had $1,167,071 (RMB 8,017,920) of notes payable from CMB, with restricted cash in the amount of $1,167,072 (RMB 8,017,920) held at the bank. As of March 31, 2018, the Company had $750,878 (RMB 4,716,037) of notes payable from CMB, with restricted cash in the amount of $750,878 (RMB 4,716,037) held at the bank.

Taxes (Tables)

Taxes (Tables)	6 Months Ended
	Sep. 30, 2018
Taxes [Abstract]
Schedule of income arising in or derived from tax jurisdiction which each entity domiciled	Entity Income Tax Jurisdiction Jo-Jo Drugstores United States Renovation Hong Kong, PRC All other entities Mainland, PRC
Schedule of components of income tax expense	For the three months ended For the six months ended September 30, September 30, 2018 2017 2018 2017 Current: Federal - - - - State - - - - Foreign (415 ) 18,047 56,754 38,585 (415 ) 18,047 56,754 38,585 Deferred: Federal - - - - State - - - - Foreign - - - - - - - - Provision for income taxes (415 ) 18,047 56,754 38,585
Schedule of reconciles the U.S. statutory tax rates with the Company's effective tax rate	For the three months ended For the six months ended September 30, September 30, 2018 2017 2018 2017 U.S. Statutory rates 21.0 % 34.0 % 21.0 % 34.0 % Foreign income not recognized in the U.S. (21.0 ) (34.0 ) (21.0 ) (34.0 ) China income taxes 25.0 25.0 25.0 25.0 Change in valuation allowance (1) (15.5 ) (18.4 ) 8.2 (22.9 ) Non-deductible expenses-permanent difference (2) (9.5 ) (8.2 ) (35.7 ) (3.6 ) Effective tax rate 0.0 % (1.6 )% (2.5 )% (1.5 )% (1) Represents a non-taxable expense due to overall increase in allowance for accounts receivable and advances to suppliers. (2) The (9.5)% and (8.2)% rate adjustments for the three months ended September 30, 2018 and 2017 and the (35.7)% and (3.6)% rate adjustments for the six months ended September 30, 2018 and 2017 represent expenses that primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible for PRC income tax.
Schedule of net deferred tax assets	As of As of Allowance 679,109 380,025 Long-lived assets impairment - - Depreciation and Amortization 139,483 147,655 Accrued expense 195,760 59,781 Net operating loss carryforward 2,858,926 1,755,691 Foreign Tax Credit Carryover 195,000 195,000 Total deferred tax assets (liabilities): 4,068,277 2,538,152 Valuation allowance (4,068,277 ) (2,538,152 ) Net deferred tax assets (liabilities) - -

Related Party Transactions an_2

Related Party Transactions and Arrangements (Tables)	6 Months Ended
	Sep. 30, 2018
Related Party Transactions and Arrangements [Abstract]
Schedule of amounts payable to related parties	September 30, March 31, Due to a director and CEO (1) 726,670 850,342 Total $ 726,670 $ 850,342 (1) Due to foreign exchange restrictions, the Company’s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States.

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Sep. 30, 2018
Warrants [Abstract]
Schedule of estimated fair value of warrants using the binominal pricing model	Common Stock Common Stock September 30, 2018 (1) March 31, Stock price $ 1.61 $ 1.35 Exercise price $ 3.10 $ 3.10 Annual dividend yield 0 % 0 % Expected term (years) 2.55 2.80 Risk-free interest rate 2.63 % 1.98 % Expected volatility 67.96 % 68.73 % (1) As of September 30, 2018, the warrants had not been exercised.

(Loss) Income Per Share (Tables

(Loss) Income Per Share (Tables)	6 Months Ended
	Sep. 30, 2018
(Loss) Income Per Share [Abstract]
Schedule of reconciliation of the basic and diluted (loss) earnings per share	Three months ended Six months ended 2018 2017 2018 2017 Net income attributable to controlling interest $ (1,587,417 ) $ (1,168,709 ) $ (2,233,270 ) $ (2,588,013 ) Weighted average shares used in basic computation 28,936,778 25,214,678 28,936,778 25,214,678 Diluted effect of purchase options and warrants - - - - Weighted average shares used in diluted computation 28,936,778 25,214,678 28,936,778 25,214,678 Income per share – Basic: Net (loss) attributable to controlling interest $ (0.06 ) $ (0.05 ) $ (0.08 ) $ (0.10 ) Loss per share – Diluted: Net (loss) attributable to controlling interest $ (0.06 ) $ (0.05 ) $ (0.08 ) $ (0.10 )

Segments (Tables)

Segments (Tables)	6 Months Ended
	Sep. 30, 2018
Segments [Abstract]
Summary of segment of the continuing operations	The following table presents summarized information by segment of the continuing operations for the three months ended September 30, 2018. Retail drugstores Online Pharmacy Drug wholesale Herb farming Total Revenue $ 18,136,298 $ 2,122,848 7,149,900 - 27,409,046 Cost of goods 13,277,943 1,909,403 6,424,599 - 21,611,945 Gross profit $ 4,858,355 $ 213,445 725,301 - 5,797,101 Selling expenses 4,156,319 477,348 589,856 - 5,223,523 General and administrative expenses 1,899,147 57,617 258,720 - 2,215,484 (Loss) income from operations $ (1,197,111 ) $ (321,520 ) (123,275 ) - (1,641,906 ) Depreciation and amortization $ 400,295 $ - 1,227 - 401,522 Total capital expenditures $ 216,443 $ - 6 - 216,449 The following table presents summarized information by segment of the continuing operations for the three months ended September 30, 2017. Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 15,047,615 $ 3,065,016 5,378,412 - 23,491,043 Cost of goods 10,804,453 2,665,299 4,463,694 - 17,933,446 Gross profit $ 4,243,162 $ 399,717 914,718 - 5,557,597 Selling expenses 2,582,089 459,785 1,308,898 - 4,350,772 General and administrative expenses 2,742,437 107,616 5,361 141 2,855,555 (Loss) income from operations $ (1,081,364 ) $ (167,684 ) (399,541 ) (141 ) (1,648,730 ) Depreciation and amortization $ (416,231 ) $ - 121,767 (119,461 ) (413,925 ) Total capital expenditures $ 149,568 $ - 45,451 - 195,019 The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2018: Retail Online Drug Herb Total Revenue $ 34,104,639 $ 4,144,717 11,932,256 50,181,612 Cost of goods 24,441,166 3,650,307 10,676,235 38,767,708 Gross profit $ 9,663,473 $ 494,410 1,256,021 11,413,904 Selling expenses 7,633,996 878,710 1,337,795 9,850,501 General and administrative expenses 3,200,615 244,841 324,556 3,770,012 (Loss) income from operations $ (1,171,138 ) $ (629,141 ) 406,330 (2,206,609 ) Depreciation and amortization $ 530,952 $ - 7,013 537,965 Total capital expenditures $ 373,715 $ - 1,123 374,838 The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2017: Retail Online Drug Herb Total Revenue $ 28,067,985 $ 6,200,705 10,892,721 45,161,411 Cost of goods 20,540,661 5,509,797 9,375,695 35,426,153 Gross profit $ 7,527,324 $ 690,908 1,517,026 9,735,258 Selling expenses 5,001,645 975,172 2,290,814 8,267,631 General and administrative expenses 4,012,213 177,905 380,833 10,047 4,580,998 (Loss) income from operations $ (1,486,534 ) $ (462,169 ) (1,154,621 ) (10,047 ) (3,113,371 ) Depreciation and amortization $ (329,242 ) $ - 204,374 (124,868 ) Total capital expenditures $ 206,142 $ - 6,216 212,358
Summary of net revenue from external customers through its retail drugstores by main products	Three months ended Six months ended 2018 2017 2018 2017 Prescription drugs $ 5,270,412 $ 4,891,435 $ 11,079,627 $ 9,486,789 OTC drugs 7,660,287 6,780,715 14,625,115 12,424,677 Nutritional supplements 1,935,456 1,638,031 2,880,662 2,675,363 TCM 1,689,697 938,688 3,272,265 1,951,199 Sundry products 345,964 362,443 550,825 624,479 Medical devices 1,234,482 436,303 1,696,145 905,478 Total $ 18,136,298 $ 15,047,615 $ 34,104,639 $ 28,067,985 Three months ended Six months ended 2018 2017 2018 2017 Prescription drugs $ - $ - $ - $ - OTC drugs 798,938 1,385,899 1,574,931 2,503,291 Nutritional supplements 211,990 334,806 355,086 850,882 TCM 20,703 10,182 25,632 10,182 Sundry products 517,123 422,388 1,554,289 841,421 Medical devices 574,094 911,741 634,779 1,994,929 Total $ 2,122,848 $ 3,065,016 $ 4,144,717 $ 6,200,705 Three months ended Six months ended 2018 2017 2018 2017 Prescription drugs $ 4,355,706 $ 3,077,232 $ 7,775,242 $ 6,474,633 OTC drugs 2,629,761 2,248,503 3,904,680 4,349,153 Nutritional supplements 48,216 12,279 73,597 28,537 TCM 57,458 604 79,309 604 Sundry products 10,775 - 15,530 - Medical devices 47,984 39,794 83,898 39,794 Total $ 7,149,900 $ 5,378,412 $ 11,932,256 $ 10,892,721

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Sep. 30, 2018
Commitments and Contingencies [Abstract]
Schedule of company's commitments for minimum rental payments	Periods ending September 30, Retail Online Drug Herb Total 2019 $ 4,363,685 $ - $ - $ - $ 4,363,685 2020 3,592,727 - - - 3,592,727 2021 2,835,408 - - - 2,835,408 2022 2,199,735 - - - 2,199,735 2023 1,440,756 - - - 1,440,756 Thereafter 2,063,945 - - - 2,063,945

Description of Business and O_3

Description of Business and Organization (Details)	6 Months Ended
	Sep. 30, 2018
Hangzhou Jiuben Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Apr. 27, 2017
Hangzhou Jiuli Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	May 22, 2017
Hangzhou Jiuxiang Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	May 26, 2017
Hangzhou Jiuheng Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jun. 6, 2017
Hangzhou Jiujiu Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jun. 8, 2017
Hangzhou Jiuyi Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jun. 8, 2017
Hangzhou Jiuyuan Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jul. 13, 2017
Hangzhou Jiumu Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jul. 21, 2017
Hangzhou Jiurui Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Aug. 4, 2017

Description of Business and O_4

Description of Business and Organization (Details 1)	6 Months Ended
	Sep. 30, 2018
Variable Interest Entity [Line Items]
Entity ownership percentage	100.00%
Renovation [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Incorporated in Hong Kong SAR on September 2, 2008
Entity ownership percentage	100.00%
Jiuxin Management [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on October 14, 2008 Deemed a wholly foreign owned enterprise ("WFOE") under PRC law Registered capital of $14.5 million fully paid
Entity ownership percentage	100.00%
Shouantang Technology [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid Deemed a WFOE under PRC law Invests and finances the working capital of Quannuo Technology
Entity ownership percentage	100.00%
Qianhong Agriculture [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on August 10, 2010 by Jiuxin Management Registered capital of RMB 10 million fully paid Carries out herb farming business
Entity ownership percentage	100.00%
Jiuzhou Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on September 9, 2003 Registered capital of RMB 5 million fully paid Operates the "Jiuzhou Grand Pharmacy" stores in Hangzhou	[1]
Entity ownership description	VIE by contractual arrangements	[2]
Jiuzhou Clinic [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC as a general partnership on October 10, 2003 Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores	[1]
Entity ownership description	VIE by contractual arrangements	[2]
Jiuzhou Service [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on November 2, 2005 Registered capital of RMB 500,000 fully paid Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores	[1]
Entity ownership description	VIE by contractual arrangements	[2]
Jiuxin Medicine [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in PRC on December 31, 2003 Acquired by Jiuzhou Pharmacy in August 2011 Registered capital of RMB 10 million fully paid Carries out pharmaceutical distribution services
Entity ownership description	VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy	[2]
Jiutong Medical [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on December 20, 2011 by Renovation Registered capital of $2.6 million fully paid Currently has no operation
Entity ownership percentage	100.00%
Jiuben Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on April 27, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuli Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on May 22, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuxiang Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on May 26, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuheng Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on June 6, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiujiu Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuyi Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on June 8, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuyuan Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on July 13, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiumu Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on July 21, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiurui Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on August, 2017 by Jiuzhou Pharmacy Registered capital of $15,920 fully paid Operates a pharmacy in Hangzhou
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Shouantang Bio [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC in October, 2014 by Shouantang Technology 100% held by Shouantang Technology Registered capital of RMB 1,000,000 fully paid Sells nutritional supplements under its own brand name
Entity ownership percentage	100.00%
Jiuyi Technology [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC on September 10, 2015 100% held by Renovation Technical support to online pharmacy
Entity ownership percentage	100.00%
Kahamadi Bio [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC in May 2016 49% held by Shouantang Bio Registered capital of RMB 10 million Develop brand name for nutritional supplements
Entity ownership percentage	49.00%
Lin'An Jiuzhou [Member]
Variable Interest Entity [Line Items]
Ownership background, description	Established in the PRC in March 31, 2017 100% held by Jiuxin Management Registered capital of RMB 5 million Explore retail pharmacy market in Lin'An City
Entity ownership percentage	100.00%
[1]	Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu, Mr. Chong'an Jin and Ms. Li Qi, the three shareholders of Renovation (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.
[2]	To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.

Description of Business and O_5

Description of Business and Organization (Details Textual)	1 Months Ended	6 Months Ended
	Sep. 17, 2009shares	Sep. 30, 2018USD ($)	Sep. 30, 2018CNY (¥)	Apr. 20, 2018USD ($)	Apr. 20, 2018CNY (¥)	May 31, 2016	Nov. 30, 2015USD ($)	Nov. 30, 2015CNY (¥)	Dec. 18, 2013
Description of Business and Organization (Textual)
Entity Incorporation, Date of Incorporation		Dec. 19, 2006
Renovation [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction	100.00%
Issuance of equity consideration, shares | shares	7,900,000
Jiuxin Management [Member]
Description of Business and Organization (Textual)
Registered capital paid		$ 14,500,000
Percentage of ownership		100.00%	100.00%
Shouantang Technology [Member]
Description of Business and Organization (Textual)
Registered capital paid		$ 20,000,000
Percentage of ownership		100.00%	100.00%
Registered capital requirement reduced		$ 11,000,000
Qianhong Agriculture [Member]
Description of Business and Organization (Textual)
Registered capital paid | ¥			¥ 10,000,000
Percentage of ownership		100.00%	100.00%
Jiuzhou Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid | ¥			¥ 5,000,000
Jiuzhou Service [Member]
Description of Business and Organization (Textual)
Registered capital paid | ¥			500,000
Percentage of ownership									51.00%
Jiuxin Medicine [Member]
Description of Business and Organization (Textual)
Issuance of equity consideration				$ 79,625	¥ 507,760
Registered capital paid | ¥			¥ 10,000,000
Percentage of ownership				10.00%	10.00%	49.00%
Jiutong Medical [Member]
Description of Business and Organization (Textual)
Registered capital paid		$ 2,600,000
Percentage of ownership		100.00%	100.00%
Shouantang Bio [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid | ¥			¥ 1,000,000
Jiuyi Technology [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Quannuo Technology [Member]
Description of Business and Organization (Textual)
Issuance of equity consideration							$ 17,121	¥ 107,074
Kahamadi Bio [Member]
Description of Business and Organization (Textual)
Registered capital paid | ¥			¥ 10,000,000
Percentage of ownership		49.00%	49.00%
Lin' An Jiuzhou [Member]
Description of Business and Organization (Textual)
Registered capital paid | ¥			¥ 5,000,000
Percentage of ownership		100.00%	100.00%
Jiuben Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid		$ 15,920
Jiumu Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid		15,920
Jiuheng Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid		15,920
Jiujiu Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid		15,920
Jiuli Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid		15,920
Jiurui Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid		15,920
Jiuxiang Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid		15,920
Jiuyi Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid		15,920
Jiuyuan Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid		$ 15,920

Liquidity (Details)

Liquidity (Details) - USD ($)	1 Months Ended
	Jan. 23, 2017	Sep. 30, 2018
Liquidity (Textual)
Bank credit line from two local banks		$ 17,610,000
Two credit line agreements [Member]
Liquidity (Textual)
Bank credit line from two local banks		$ 1,520,000
Private Placement [Member]
Liquidity (Textual)
Purchase of aggregate of common stock	4,840,000
Common stock price, per share	$ 2.20
Gross proceeds from private placement	$ 10,648,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	Sep. 30, 2018USD ($)
Summary of fair values of derivative instruments
Cash and cash equivalents	$ 6,922,357
Notes payable	15,509,129
Warrants liability	227,635
Total	22,659,121
Active Market for Identical Assets (Level 1) [Member]
Summary of fair values of derivative instruments
Cash and cash equivalents	6,922,357
Notes payable
Warrants liability
Total	6,922,357
Observable Inputs (Level 2) [Member]
Summary of fair values of derivative instruments
Cash and cash equivalents
Notes payable	15,509,129
Warrants liability	227,635
Total	15,736,764
Unobservable Inputs (Level 3) [Member]
Summary of fair values of derivative instruments
Cash and cash equivalents
Notes payable
Warrants liability
Total

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1)	6 Months Ended
	Sep. 30, 2018
Leasehold improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	10 years
Leasehold improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Motor vehicles [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	5 years
Motor vehicles [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Office equipment & furniture [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	5 years
Office equipment & furniture [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Buildings [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	35 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2)	6 Months Ended
	Sep. 30, 2018
Land use rights [Member]
Schedule of estimated useful lives of intangible assets
Estimated useful life of intangible assets	50 years
Software [Member]
Schedule of estimated useful lives of intangible assets
Estimated useful life of intangible assets	3 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 3) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Total revenue	$ 27,409,046	$ 23,491,043	$ 50,181,612	$ 45,161,411
Retail drugstores [Member]
Disaggregation of Revenue [Line Items]
Total revenue	18,136,298	15,047,615	34,104,639	28,067,985
Retail drugstores [Member] | Prescription drugs [Member]
Disaggregation of Revenue [Line Items]
Total revenue	5,270,412	4,891,435	11,079,627	9,486,789
Retail drugstores [Member] | OTC drugs [Member]
Disaggregation of Revenue [Line Items]
Total revenue	7,660,287	6,780,715	14,625,115	12,424,677
Retail drugstores [Member] | Nutritional supplements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,935,456	1,638,031	2,880,662	2,675,363
Retail drugstores [Member] | TCM [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,689,697	938,688	3,272,265	1,951,199
Retail drugstores [Member] | Sundry products [Member]
Disaggregation of Revenue [Line Items]
Total revenue	345,964	362,443	550,825	624,479
Retail drugstores [Member] | Medical devices [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,234,482	436,303	1,696,145	905,478
Online pharmacy [Member]
Disaggregation of Revenue [Line Items]
Total revenue	2,122,848	3,065,016	4,144,717	6,200,705
Online pharmacy [Member] | Prescription drugs [Member]
Disaggregation of Revenue [Line Items]
Total revenue
Online pharmacy [Member] | OTC drugs [Member]
Disaggregation of Revenue [Line Items]
Total revenue	798,938	1,385,899	1,574,931	2,503,291
Online pharmacy [Member] | Nutritional supplements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	211,990	334,806	355,086	850,882
Online pharmacy [Member] | TCM [Member]
Disaggregation of Revenue [Line Items]
Total revenue	20,703	10,182	25,632	10,182
Online pharmacy [Member] | Sundry products [Member]
Disaggregation of Revenue [Line Items]
Total revenue	517,123	422,388	1,554,289	841,421
Online pharmacy [Member] | Medical devices [Member]
Disaggregation of Revenue [Line Items]
Total revenue	574,094	911,741	634,779	1,994,929
Drug wholesale [Member]
Disaggregation of Revenue [Line Items]
Total revenue	7,149,900	5,378,412	11,932,256	10,892,721
Drug wholesale [Member] | Prescription drugs [Member]
Disaggregation of Revenue [Line Items]
Total revenue	4,355,706	3,077,232	7,775,242	6,474,633
Drug wholesale [Member] | OTC drugs [Member]
Disaggregation of Revenue [Line Items]
Total revenue	2,629,761	2,248,503	3,904,680	4,349,153
Drug wholesale [Member] | Nutritional supplements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	48,216	12,279	73,597	28,537
Drug wholesale [Member] | TCM [Member]
Disaggregation of Revenue [Line Items]
Total revenue	57,458	604	79,309	604
Drug wholesale [Member] | Sundry products [Member]
Disaggregation of Revenue [Line Items]
Total revenue	10,775		15,530
Drug wholesale [Member] | Medical devices [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 47,984	$ 39,794	$ 83,898	$ 39,794

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details 4) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Summary of Significant Accounting Policies [Abstract]
Trade receivable(included in accounts receivable, net)	$ 7,830,713	$ 8,322,393
Contract liabilities (included in accrued expenses)	$ 5,176,002	$ 4,461,136

Summary of Significant Accoun_9

Summary of Significant Accounting Policies (Details 5) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Condensed Consolidated Statement of Operations:
Net revenues	$ 27,409,046	$ 23,491,043	$ 50,181,612	$ 45,161,411
Cost of revenues	21,611,945	17,933,446	38,767,708	35,426,153
Gross profit	5,797,101	5,557,597	11,413,904	9,735,258
SELLING EXPENSES	5,223,523	4,350,772	9,850,501	8,267,631
GENERAL AND ADMINISTRATIVE EXPENSES	2,215,484	2,855,555	3,770,012	4,580,998
Operating profit	(1,641,906)	(1,648,730)	(2,206,609)	(3,113,371)
Income (loss) before income tax provision	(1,603,130)	(1,150,662)	(2,242,576)	(2,549,428)
Income tax provision	(415)	18,047	56,754	38,585
Net income (loss)	(1,602,715)	$ (1,168,709)	(2,299,330)	$ (2,588,013)
As Reported Balances [Member]
Condensed Consolidated Statement of Operations:
Net revenues	27,409		50,182
Cost of revenues	21,612		38,768
Gross profit	5,797		11,414
SELLING EXPENSES	5,224		9,851
GENERAL AND ADMINISTRATIVE EXPENSES	2,215		3,770
Operating profit	(1,642)		(2,207)
Income (loss) before income tax provision	(1,603)		(2,243)
Income tax provision			57
Income (loss) from continuing operations	(1,603)		(2,299)
Net income (loss)	(1,603)		(2,299)
Adjustments [Member]
Condensed Consolidated Statement of Operations:
Net revenues	(37)		144
Cost of revenues
Gross profit	(37)		144
SELLING EXPENSES	37		(144)
GENERAL AND ADMINISTRATIVE EXPENSES
Operating profit
Income (loss) before income tax provision
Income tax provision
Income (loss) from continuing operations
Net income (loss)
Balance without Adoption of Topic 606 [Member]
Condensed Consolidated Statement of Operations:
Net revenues	27,372		50,326
Cost of revenues	21,612		38,768
Gross profit	5,760		11,558
SELLING EXPENSES	5,187		9,995
GENERAL AND ADMINISTRATIVE EXPENSES	2,215		3,770
Operating profit	(1,642)		(2,207)
Income (loss) before income tax provision	(2,243)		(2,243)
Income tax provision			57
Income (loss) from continuing operations	(1,603)		(2,299)
Net income (loss)	$ (1,603)		$ (2,299)

Summary of Significant Accou_10

Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		6 Months Ended
	Sep. 30, 2018USD ($)Vendors	Sep. 30, 2017USD ($)Vendors	Sep. 30, 2018USD ($)Vendors	Sep. 30, 2017USD ($)VendorsSupplier	Sep. 30, 2018CNY (¥)	Mar. 31, 2018USD ($)	Mar. 31, 2015USD ($)	Mar. 31, 2015CNY (¥)
Summary of Significant Accounting Policies (Textual)
Voting ownership interest			50.00%
Ownership percentage			100.00%
Value added tax, percentage			16.00%
Income tax, description			The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company performed a self-assessment and the Company's liability for income taxes includes liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years.
Advertising and promotion costs | $	$ 213,382	$ 180,639	$ 405,409	$ 320,734
Term of agreement for operating leases	30 years		30 years		30 years
Foreign currency translation, description			The balance sheet amounts, with the exception of equity, at September 30, 2018 and at March 31, 2018 were translated at 1 RMB to 0.1456 USD and at 1 RMB to 0.1592 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2018 and 2017 were at 1 RMB to 0.1518 USD and at 1 RMB to 0.1478 USD, respectively.
Insurance covered by own bank							$ 75,916	¥ 500,000
Deposits | $	$ 23,688,866		$ 23,688,866			$ 31,433,969
Deposits not covered by insurance	$ 75,916		$ 75,916		¥ 500,000
Total purchases [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	56.60%	61.30%	42.40%	39.60%
Number of vendors | Vendors	3	3	2	2
Total advances to suppliers [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	23.30%	16.80%	10.00%	10.00%
Number of vendors | Vendors	1	1	2
Number of supplier | Supplier				2
Total sales [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	10.00%	10.00%	10.00%	10.00%
Total accounts receivable [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	10.00%	10.00%	10.00%	10.00%
Retail drugstores [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Term of agreement for operating leases	3 years		3 years		3 years
Retail drugstores [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Term of agreement for operating leases	10 years		10 years		10 years
Wholesale warehouse [Member]
Summary of Significant Accounting Policies (Textual)
Term of agreement for operating leases	10 years		10 years		10 years

Financial Assets Available fo_2

Financial Assets Available for Sale (Details)	Sep. 30, 2018USD ($)	Sep. 30, 2018CNY (¥)	Mar. 31, 2018USD ($)	Mar. 31, 2018CNY (¥)
Financial Assets Available for Sale (Textual)
Financial assets available for sale	$ 162,224	¥ 1,114,500	$ 175,140	¥ 1,100,000
Investment agreement fund			295,096	2,000,000
Invested total amount			74,890
Songlu Pharmaceutical [Member]
Financial Assets Available for Sale (Textual)
Invested total amount			$ 87,334	¥ 600,000
Percentage of shares			0.50%	0.50%

Trade Accounts Receivable (Deta

Trade Accounts Receivable (Details) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Trade Accounts Receivable [Abstract]
Accounts receivable	$ 12,351,161	$ 12,883,707
Less: allowance for doubtful accounts	(4,520,448)	(4,561,314)
Trade accounts receivable, net	$ 7,830,713	$ 8,322,393

Trade Accounts Receivable (De_2

Trade Accounts Receivable (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Trade Accounts Receivable (Textual)
Accounts receivable written off	$ 33,829	$ 98,590	$ 64,412	$ 124,983

Other Current Assets (Details)

Other Current Assets (Details) - USD ($)		Sep. 30, 2018	Mar. 31, 2018
Other Current Assets [Abstract]
Prepaid rental expenses	[1]	$ 1,296,782	$ 1,984,856
Prepaid and other current assets		187,326	131,381
Total		$ 1,484,108	$ 2,116,237
[1]	Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period.

Property and Equipment (Details

Property and Equipment (Details) - USD ($)		Sep. 30, 2018	Mar. 31, 2018
Property, Plant and Equipment [Line Items]
Total		$ 15,963,989	$ 17,255,788
Less: Accumulated depreciation		(11,133,655)	(11,905,893)
Impairment	[1]	(2,291,433)	(2,506,255)
Property and equipment, net		2,538,901	2,843,640
Building [Member]
Property, Plant and Equipment [Line Items]
Total		1,560,683	1,707,145
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total		7,187,866	7,606,496
Farmland development cost [Member]
Property, Plant and Equipment [Line Items]
Total		1,740,785	1,904,151
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Total		5,056,136	5,581,554
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Total		$ 418,519	$ 456,442
[1]	The variance of impairment from March 31, 2018 to September 30, 2018 is solely caused by exchange rate variance.

Property and Equipment (Detai_2

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property and Equipment (Textual)
Depreciation expenses for property and equipment	$ 212,214	$ 171,051	$ 431,973	$ 576,154

Advances to Suppliers (Details)

Advances to Suppliers (Details) - USD ($)		Sep. 30, 2018	Mar. 31, 2018
Advances to Suppliers [Abstract]
Advance to suppliers	[1]	$ 6,533,976	$ 6,505,545
Less: allowance for unrefundable advances		(3,299,037)	(3,058,092)
Advance to suppliers, net		$ 3,234,939	$ 3,447,452
[1]	In order to achieve a larger rebate for certain merchandise, such as colla coril asini (donkey-hide gelatin), from certain suppliers, the Company made a significant cash advance to such suppliers.

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Inventory (Textual)
Finished goods	$ 13,799,438	$ 13,429,568

Farmland Assets (Details)

Farmland Assets (Details) - USD ($)		Sep. 30, 2018	Mar. 31, 2018
Farmland Assets [Abstract]
Farmland assets		$ 2,216,471	$ 2,416,839
Less: Impairment	[1]	(1,481,520)	(1,620,553)
Farmland assets, net		$ 734,951	$ 796,286
[1]	The estimated fair value is estimated to be lower than its investment value as of September 30, 2018 and March 31, 2018.

Long Term Deposits, Landlords (

Long Term Deposits, Landlords (Details) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Long Term Deposits, Landlords (Textual)
Long term deposits	$ 2,269,241	$ 2,501,968

Other Noncurrent Assets (Detail

Other Noncurrent Assets (Details) - USD ($)		Sep. 30, 2018	Mar. 31, 2018
Other Noncurrent Assets [Abstract]
Forest land use rights	[1]	$ 1,129,275	$ 1,235,253
Others		150,376	18,099
Total		$ 1,279,651	$ 1,253,352
[1]	The prepayment for lease of forest land use rights is a payment made to a local government in connection with entering into an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060.

Other Noncurrent Assets (Deta_2

Other Noncurrent Assets (Details 1)	Sep. 30, 2018USD ($)
For the year ending September 30,
2,019	$ 28,529
2,020	28,529
2,021	28,529
2,022	28,529
2,023	28,529
Thereafter	$ 986,630

Other Noncurrent Assets (Deta_3

Other Noncurrent Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Other Noncurrent Assets (Textual)
Amortization of prepayment for lease of land use right	$ 6,579	$ 7,042	$ 13,675	$ 13,888
Description of lease prepayment life			Extends the life of the lease to January 31, 2060.

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)		Sep. 30, 2018	Mar. 31, 2018
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets		$ 3,917,060	$ 4,284,660
Less: accumulated amortization		(350,016)	(228,246)
Intangible assets, net		3,567,044	4,056,414
License [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets	[1]	1,994,508	1,967,934
SAP software [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets	[2]	503,136	764,104
Land use rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets	[3]	$ 1,419,416	$ 1,552,622
[1]	This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy, a drugstore chain Jiuzhou Pharmacy acquired in 2014. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. The owners of these acquired drugstores agreed to cease their stores' business and liquidate all of the stores' accounts before Jiuzhou Pharmacy acquired them. As a result, Jiuzhou Pharmacy has not obtained any assets or liabilities from the stores, but was able to transfer the certificates to our new stores opened at the same time.
[2]	In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. As of September 30, 2018, the system has been completely installed and running for eight months in the Company. By automatically connecting commodity flow data with accounting recording, the system minimizes the manual errors made by accounting staff. Additionally, the system provides a view of overall and instant cash information by electronically linking local banking systems with SAP. Additional benefits include automatically-generated customized monthly company performance reports, instant inventory monitoring and reporting, and punctual maintenance of customer and supplier accounts.
[3]	In July 2013, the Company purchased the land use rights of a plot of farmland in Lin'an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin'an has not grown, the Company does not expect completion of the plant in the near future.

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Intangible Assets (Textual)
Amortization expense of intangibles	$ 87,478	$ 7,334	$ 161,187	$ 14,464

Notes Payable (Details)

Notes Payable (Details) - USD ($)		6 Months Ended
		Sep. 30, 2018	Mar. 31, 2018
Short-term Debt [Line Items]
Notes payable		$ 15,509,129	$ 19,180,200
Jiuzhou Pharmacy [Member] | HUB [Member] | 10/10/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 10, 2018
Notes payable	[1]		2,552,769
Jiuzhou Pharmacy [Member] | HUB [Member] | 11/24/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	May 24, 2018
Notes payable	[1]		21,972
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/05/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 5, 2018
Notes payable	[1]		377,347
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/29/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 29, 2018
Notes payable	[1]		1,194,135
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/29/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 29, 2018
Notes payable	[1]		1,443,554
Jiuzhou Pharmacy [Member] | HUB [Member] | 02/05/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Aug. 5, 2018
Notes payable	[1]		2,618,500
Jiuzhou Pharmacy [Member] | HUB [Member] | 03/05/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Sep. 5, 2018
Notes payable	[1]		3,072,638
Jiuzhou Pharmacy [Member] | HUB [Member] | 11/06/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	May 6, 2018
Notes payable	[1]		3,553,014
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/05/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 5, 2018
Notes payable	[1]		1,937,683
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/29/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 29, 2018
Notes payable	[1]		1,687,711
Jiuzhou Pharmacy [Member] | HUB [Member] | 04/09/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Oct. 9, 2018
Notes payable	[1]	$ 1,502,176
Jiuzhou Pharmacy [Member] | HUB [Member] | 05/04/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Nov. 4, 2018
Notes payable	[1]	$ 2,167,359
Jiuzhou Pharmacy [Member] | HUB [Member] | 06/29/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Dec. 29, 2018
Notes payable	[1]	$ 1,860,231
Jiuzhou Pharmacy [Member] | HUB [Member] | 07/05/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jan. 5, 2019
Notes payable	[1]	$ 2,993,503
Jiuzhou Pharmacy [Member] | HUB [Member] | 08/06/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Feb. 6, 2019
Notes payable	[1]	$ 1,358,819
Jiuzhou Pharmacy [Member] | HUB [Member] | 08/17/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Feb. 17, 2019
Notes payable	[1]	$ 278,003
Jiuzhou Pharmacy [Member] | HUB [Member] | 08/31/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Feb. 28, 2019
Notes payable	[1]	$ 2,303,019
Jiuzhou Pharmacy [Member] | HUB [Member] | 09/05/18 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Mar. 5, 2019
Notes payable	[1]	$ 1,878,948
Jiuxin Medicine [Member] | CMB [Member] | 02/02/18 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Aug. 2, 2018
Notes payable	[2]		71,648
Jiuxin Medicine [Member] | CMB [Member] | 02/07/18 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Aug. 7, 2018
Notes payable	[2]		95,531
Jiuxin Medicine [Member] | CMB [Member] | 03/07/18 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Sep. 7, 2018
Notes payable	[2]		538,857
Jiuxin Medicine [Member] | CMB [Member] | 03/15/18 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Sep. 15, 2018
Notes payable	[2]		44,842
Jiuxin Medicine [Member] | CMB [Member] | 04/09/18 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Oct. 9, 2018
Notes payable	[2]	$ 282,080
Jiuxin Medicine [Member] | CMB [Member] | 05/14/18 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Nov. 14, 2018
Notes payable	[2]	$ 884,991
[1]	As of September 30, 2018, the Company had $14,342,058 (RMB 98,531,558) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $14,342,058 (RMB 98,531,558) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $10,206,912 three-year deposit (RMB 70,122,647) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2018, the Company had $18,429,322 (RMB 115,748,985) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $13,565,300 (RMB 85,199,540) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $7,269,509 three-year deposit (RMB 45,657,584) deposited into HUB as a collateral for current and future notes payable from HUB.
[2]	As of September 30, 2018, the Company had $1,167,071 (RMB 8,017,920) of notes payable from CMB, with restricted cash in the amount of $1,167,072 (RMB 8,017,920) held at the bank. As of March 31, 2018, the Company had $750,878 (RMB 4,716,037) of notes payable from CMB, with restricted cash in the amount of $750,878 (RMB 4,716,037) held at the bank.

Notes Payable (Details Textual)

Notes Payable (Details Textual)	6 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2018CNY (¥)	Mar. 31, 2018USD ($)	Mar. 31, 2018CNY (¥)
Notes Payable (Textual)
Notes payable	$ 15,510,000
Line of credit total	17,610,000
Bank credit line facilities available for borrowing	2,100,000
HUB [Member]
Notes Payable (Textual)
Notes payable	10,210,000
Restricted cash	3,760,000
Line of credit total	$ 3,640,000
Term of deposit	3 years
Notes Payable [Member] | HUB [Member]
Notes Payable (Textual)
Notes payable	$ 14,342,058	¥ 98,531,558	$ 18,429,322	¥ 115,748,985
Restricted cash	14,342,058	98,531,558	13,565,300	85,199,540
Notes Payable [Member] | HUB One [Member]
Notes Payable (Textual)
Restricted cash	10,206,912	70,122,647	7,269,509	45,657,584
Notes Payable [Member] | CMB [Member]
Notes Payable (Textual)
Notes payable	1,167,071	8,017,920	750,878	4,716,037
Restricted cash	$ 1,167,072	¥ 8,017,920	$ 750,878	¥ 4,716,037

Taxes (Details)

Taxes (Details)	6 Months Ended
	Sep. 30, 2018
Jo-Jo Drugstores [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	United States
Renovation [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	Hong Kong, PRC
All other entities [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	Mainland, PRC

Taxes (Details 1)

Taxes (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Current:
Federal
State
Foreign	$ (415)	$ 18,047	56,754	38,585
Total	(415)	18,047	56,754	38,585
Deferred:
Federal
State
Foreign
Provision for income taxes	$ (415)	$ 18,047	$ 56,754	$ 38,585

Taxes (Details 2)

Taxes (Details 2)		3 Months Ended		6 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Taxes [Abstract]
U.S. Statutory rates		21.00%	34.00%	21.00%	34.00%
Foreign income not recognized in the U.S.		(21.00%)	(34.00%)	(21.00%)	(34.00%)
China income taxes		25.00%	25.00%	25.00%	25.00%
Change in valuation allowance	[1]	(15.50%)	(18.40%)	8.20%	(22.90%)
Non-deductible expenses-permanent difference	[2]	(9.50%)	(8.20%)	(35.70%)	(3.60%)
Effective tax rate		0.00%	(1.60%)	(2.50%)	(1.50%)
[1]	Represents a non-taxable expense due to overall increase in allowance for accounts receivable and advances to suppliers.
[2]	The (9.5)% and (8.2)% rate adjustments for the three months ended September 30, 2018 and 2017 and the (35.7)% and (3.6)% rate adjustments for the six months ended September 30, 2018 and 2017 represent expenses that primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible for PRC income tax.

Taxes (Details 3)

Taxes (Details 3) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Taxes [Abstract]
Allowance	$ 679,109	$ 380,025
Long-lived assets impairment
Depreciation and Amortization	139,483	147,655
Accrued expense	195,760	59,781
Net operating loss carryforward	2,858,926	1,755,691
Foreign Tax Credit Carryover	195,000	195,000
Total deferred tax assets (liabilities):	4,068,277	2,538,152
Valuation allowance	(4,068,277)	(2,538,152)
Net deferred tax assets (liabilities)

Taxes (Details Textual)

Taxes (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 22, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 31, 2018
Taxes (Textual)
Estimated net operating loss carry forwards for U.S. income tax purposes		$ 2,858,926	$ 1,755,691	$ 2,858,926	$ 1,755,691
Expiration date				Mar. 31, 2032
Valuation allowance, percentage				100.00%
Effective tax rate		0.00%	(1.60%)	(2.50%)	(1.50%)
Foreign tax credit				$ 195,000
Income tax, description	The U.S. federal statutory rate from 35% to 21%, effective on January 1, 2018. ASC 740 requires companies to recognize the effect of tax law changes in the period of enactment, accordingly, the effects must be recognized on companies' calendar year-end financial statements, even though the effective date for most provisions is January 1, 2018. As a result, we re-measured our net U.S. deferred tax assets at the 21% future tax rate.			Audit periods remain open for review until the statute of limitations has passed, which in the PRC, the Company's most significant tax jurisdiction, is usually 5 years.
Net unrecognized tax benefits						$ 0
Percentage of corporate tax rate				21.00%
U.S. income tax [Member]
Taxes (Textual)
Estimated net operating loss carry forwards for U.S. income tax purposes		$ 816,908	$ 816,908	$ 816,908	$ 816,908
Expiration date				Mar. 31, 2032
China Income Tax [Member]
Taxes (Textual)
Estimated net operating loss carry forwards for U.S. income tax purposes		13,553,030	7,097,939	$ 13,553,030	7,097,939
Hong Kong Income Tax [Member]
Taxes (Textual)
Estimated net operating loss carry forwards for U.S. income tax purposes		1,899,812	$ 1,713,633	1,899,812	$ 1,713,633
Jo-Jo Drugstores [Member]
Taxes (Textual)
Estimated net operating loss carry forwards for U.S. income tax purposes		$ 1,503,000		$ 1,503,000

Postretirement Benefits (Detail

Postretirement Benefits (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Postretirement Benefits (Textual)
Employment benefits and pension contribution	$ 346,876	$ 276,490	$ 712,512	$ 559,734

Related Party Transactions an_3

Related Party Transactions and Arrangements (Details) - USD ($)		Sep. 30, 2018	Mar. 31, 2018
Related Party Transaction [Line Items]
Total		$ 726,670	$ 850,342
Due to a director and CEO [Member]
Related Party Transaction [Line Items]
Total	[1]	$ 726,670	$ 850,342
[1]	Due to foreign exchange restrictions, the Company's director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States.

Related Party Transactions an_4

Related Party Transactions and Arrangements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2018
Related Party Transactions and Arrangements (Textual)
Notes payable, related parties	$ 0		$ 0		$ 3,253,630
Mr. Lei Liu [Member]
Related Party Transactions and Arrangements (Textual)
Lease expiration date			Sep. 30, 2018
Rent expenses	$ 4,578	$ 4,435	$ 9,110	$ 8,870

Warrants (Details)

Warrants (Details) - Common Stock Warrants [Member] - $ / shares	6 Months Ended		12 Months Ended
	Sep. 30, 2018	[1]	Mar. 31, 2018
Class of Warrant or Right [Line Items]
Stock price	$ 1.61		$ 1.35
Exercise price	$ 3.10		$ 3.10
Annual dividend yield	0.00%		0.00%
Expected term (years)	2 years 6 months 18 days		2 years 9 months 18 days
Risk-free interest rate	2.63%		1.98%
Expected volatility	67.96%		68.73%
[1]	As of September 30, 2018, the warrants had not been exercised.

Warrants (Details Textual)

Warrants (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Jul. 19, 2015	Sep. 30, 2018	Sep. 30, 2018	Mar. 31, 2018
Warrants (Textual)
Fair value estimation method			Binominal pricing model
Fair value of warrant liability				$ 138,796
Purchase of warrants investors			672,000
Recognized gain on fair value of warrant liability investor placement agent		$ 81,865	$ 88,840
Fair value of warrant liability investor placement agent			$ 227,635
Warrants [Member]
Warrants (Textual)
Stock purchase price per share (in dollars per share)	$ 3.10
Warrants exercisable date	Jan. 19, 2016
Maturity date	Jan. 18, 2021
Purchase of warrants investors	600,000
Issuance of warrants to placement agent			72,000
Percentage of stock sold in offering			6.00%

Stockholder's Equity (Details)

Stockholder's Equity (Details)	Nov. 18, 2014Segment$ / sharesshares	Jun. 28, 2018shares	Mar. 30, 2018shares	Jan. 23, 2017USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Mar. 31, 2018USD ($)
Stockholder's Equity (Textual)
Reserve fund percentage							50.00%
Statutory accounts percentage							10.00%
Compensation committee cancelled shares		225,000
CEO [Member]
Stockholder's Equity (Textual)
Aggregate issuances shares		675,000
Performance based compensation exemption, description		The Tax Cuts and Jobs Act of 2017 removed the 162(m) qualified performance based compensation exemption to the $1 million cap on deductions for compensation to covered executives.
Common Stock [Member]
Stockholder's Equity (Textual)
Company sold common stock to investor				4,840,000
Common stock, par value | $ / shares				$ 0.001
Purchase price | $ / shares				$ 2.20
Proceeds from private placement | $				$ 10,648,000
Stock option [Member]
Stockholder's Equity (Textual)
Number of granted shares	967,000
Share based compensation expense | $					$ 0	$ 221,859	$ 0	$ 441,306
Number of directors, officers and employees in a group | Segment	46
Exercise price of stock option | $ / shares	$ 2.50
Period for options exercisable from the vesting date	5 years
Maturity date	Nov. 17, 2022
2010 Equity Incentive Plan [Member]
Stockholder's Equity (Textual)
Number of granted shares			3,947,100
Share based compensation expense | $									$ 5,328,585

(Loss) Income Per Share (Detail

(Loss) Income Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
(Loss) Income Per Share [Abstract]
Net income attributable to controlling interest	$ (1,602,715)	$ (1,168,709)	$ (2,299,330)	$ (2,588,013)
Weighted average shares used in basic computation	28,936,778	25,214,678	28,936,778	25,214,678
Diluted effect of purchase options and warrants
Weighted average shares used in diluted computation	28,936,778	25,214,678	28,936,778	25,214,678
Income per share - Basic:
Net (loss) attributable to controlling interest	$ (0.06)	$ (0.05)	$ (0.08)	$ (0.1)
Loss per share - Diluted:
Net (loss) attributable to controlling interest	$ (0.06)	$ (0.05)	$ (0.08)	$ (0.1)

(Loss) Income Per Share (Deta_2

(Loss) Income Per Share (Details Textual) - Stock options [Member] - shares	3 Months Ended	6 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
(Loss) Income Per Share (Textual)
Antidilutive securities excluded from calculation of diluted earnings per share	967,000	967,000
Investment placement agent [Member]
(Loss) Income Per Share (Textual)
Antidilutive securities excluded from calculation of diluted earnings per share	72,000	72,000
Investor [Member]
(Loss) Income Per Share (Textual)
Antidilutive securities excluded from calculation of diluted earnings per share	600,000	600,000

Segments (Details)

Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information [Line Items]
Revenue	$ 27,409,046	$ 23,491,043	$ 50,181,612	$ 45,161,411
Cost of goods	21,611,945	17,933,446	38,767,708	35,426,153
Gross profit	5,797,101	5,557,597	11,413,904	9,735,258
Selling expenses	5,223,523	4,350,772	9,850,501	8,267,631
General and administrative expenses	2,215,484	2,855,555	3,770,012	4,580,998
(Loss) income from operations	(1,641,906)	(1,648,730)	(2,206,609)	(3,113,371)
Depreciation and amortization	401,522	(413,925)	537,965	(124,868)
Total capital expenditures	216,449	195,019	374,838	212,358
Retail drugstores [Member]
Segment Reporting Information [Line Items]
Revenue	18,136,298	15,047,615	34,104,639	28,067,985
Cost of goods	13,277,943	10,804,453	24,441,166	20,540,661
Gross profit	4,858,355	4,243,162	9,663,473	7,527,324
Selling expenses	4,156,319	2,582,089	7,633,996	5,001,645
General and administrative expenses	1,899,147	2,742,437	3,200,615	4,012,213
(Loss) income from operations	(1,197,111)	(1,081,364)	(1,171,138)	(1,486,534)
Depreciation and amortization	400,295	(416,231)	530,952	(329,242)
Total capital expenditures	216,443	149,568	373,715	206,142
Online Pharmacy [Member]
Segment Reporting Information [Line Items]
Revenue	2,122,848	3,065,016	4,144,717	6,200,705
Cost of goods	1,909,403	2,665,299	3,650,307	5,509,797
Gross profit	213,445	399,717	494,410	690,908
Selling expenses	477,348	459,785	878,710	975,172
General and administrative expenses	57,617	107,616	244,841	177,905
(Loss) income from operations	(321,520)	(167,684)	(629,141)	(462,169)
Depreciation and amortization
Total capital expenditures
Drug wholesale [Member]
Segment Reporting Information [Line Items]
Revenue	7,149,900	5,378,412	11,932,256	10,892,721
Cost of goods	6,424,599	4,463,694	10,676,235	9,375,695
Gross profit	725,301	914,718	1,256,021	1,517,026
Selling expenses	589,856	1,308,898	1,337,795	2,290,814
General and administrative expenses	258,720	5,361	324,556	380,833
(Loss) income from operations	(123,275)	(399,541)	406,330	(1,154,621)
Depreciation and amortization	1,227	121,767	7,013	204,374
Total capital expenditures	6	45,451	1,123	6,216
Herb farming [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of goods
Gross profit
Selling expenses
General and administrative expenses		141		10,047
(Loss) income from operations		(141)		(10,047)
Depreciation and amortization		(119,461)
Total capital expenditures

Segments (Details 1)

Segments (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 27,409,046	$ 23,491,043	$ 50,181,612	$ 45,161,411
Retail drugstores [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	18,136,298	15,047,615	34,104,639	28,067,985
Retail drugstores [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	5,270,412	4,891,435	11,079,627	9,486,789
Retail drugstores [Member] | OTC drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	7,660,287	6,780,715	14,625,115	12,424,677
Retail drugstores [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,935,456	1,638,031	2,880,662	2,675,363
Retail drugstores [Member] | TCM [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,689,697	938,688	3,272,265	1,951,199
Retail drugstores [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	345,964	362,443	550,825	624,479
Retail drugstores [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,234,482	436,303	1,696,145	905,478
Online pharmacy [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	2,122,848	3,065,016	4,144,717	6,200,705
Online pharmacy [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers
Online pharmacy [Member] | OTC drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	798,938	1,385,899	1,574,931	2,503,291
Online pharmacy [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	211,990	334,806	355,086	850,882
Online pharmacy [Member] | TCM [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	20,703	10,182	25,632	10,182
Online pharmacy [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	517,123	422,388	1,554,289	841,421
Online pharmacy [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	574,094	911,741	634,779	1,994,929
Drug wholesale [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	7,149,900	5,378,412	11,932,256	10,892,721
Drug wholesale [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	4,355,706	3,077,232	7,775,242	6,474,633
Drug wholesale [Member] | OTC drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	2,629,761	2,248,503	3,904,680	4,349,153
Drug wholesale [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	48,216	12,279	73,597	28,537
Drug wholesale [Member] | TCM [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	57,458	604	79,309	604
Drug wholesale [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	10,775		15,530
Drug wholesale [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 47,984	$ 39,794	$ 83,898	$ 39,794

Segments (Details Textual)

Segments (Details Textual)	6 Months Ended
	Sep. 30, 2018Segment
Segments (Textual)
Number of operating segments	4

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Sep. 30, 2018USD ($)
Commitments and Contingencies [Line Items]
2,019	$ 4,363,685
2,020	3,592,727
2,021	2,835,408
2,022	2,199,735
2,023	1,440,756
Thereafter	2,063,945
Retail drugstores [Member]
Commitments and Contingencies [Line Items]
2,019	4,363,685
2,020	3,592,727
2,021	2,835,408
2,022	2,199,735
2,023	1,440,756
Thereafter	2,063,945
Online pharmacy [Member]
Commitments and Contingencies [Line Items]
2,019
2,020
2,021
2,022
2,023
Thereafter
Drug wholesale [Member]
Commitments and Contingencies [Line Items]
2,019
2,020
2,021
2,022
2,023
Thereafter
Herb farming [Member]
Commitments and Contingencies [Line Items]
2,019
2,020
2,021
2,022
2,023
Thereafter

Commitments and Contingencies_3

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Commitments and Contingencies (Textual)
Total rent expenses	$ 1,155,529	$ 1,076,749	$ 2,310,622	$ 1,887,461

Subsequent Events (Details)

Subsequent Events (Details)	Oct. 09, 2018
Subsequent Event [Member]
Subsequent Event [Line Items]
Credit line agreement, description	A new credit line agreement with Hangzhou United Bank for a credit line up to $5,094,530 (RMB 35,000,000) for a period from October 9, 2018 to October 8, 2020.